BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:v56-68. [DOI: 10.1093/annonc/mdv295] [Cited by in Crossref: 525] [Cited by in F6Publishing: 477] [Article Influence: 75.0] [Reference Citation Analysis]
Number Citing Articles
1 Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) 2020;12:E3866. [PMID: 33371464 DOI: 10.3390/cancers12123866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Masetti M, Acquaviva G, Visani M, Tallini G, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S, Fiorino S, Lombardi R, Tuminati D, Ravaioli M, Fabbri C, Bacchi-Reggiani ML, Pession A, Jovine E, de Biase D. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomark. 2018;21:323-334. [PMID: 29103024 DOI: 10.3233/cbm-170464] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
3 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
4 Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, Aly A, Botteman M, Romano A, Ferrara S, Margunato-debay S, Harris M. nab -Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia-Pac J Clin Oncol 2018;14:e325-31. [DOI: 10.1111/ajco.12999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Liang H, Xie W, Lin X, Wang T, Xie J, Wang C, Xiao SY, Guo Y. Pathologic T1 and T2 encapsulated invasive carcinomas arising from mucinous cystic neoplasms of the pancreas have favorable prognosis and might be treated conservatively. J Pathol Clin Res 2021;7:507-16. [PMID: 34062050 DOI: 10.1002/cjp2.225] [Reference Citation Analysis]
6 Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. Br J Cancer 2017;116:1247-53. [PMID: 28350787 DOI: 10.1038/bjc.2017.67] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
7 Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Ann Oncol 2020;31:1336-49. [PMID: 32710930 DOI: 10.1016/j.annonc.2020.07.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
8 Machicado JD, Obuch JC, Goodman KA, Schefter TE, Frakes J, Hoffe S, Latifi K, Simon VC, Santangelo T, Ezekwe E, Edmundowicz SA, Brauer BC, Shah RJ, Hammad HT, Wagh MS, Attwell A, Han S, Klapman J, Wani S. Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. Clin Gastroenterol Hepatol 2019;17:2749-2758.e2. [PMID: 31042578 DOI: 10.1016/j.cgh.2019.04.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liu XJ, Yang T, Shi X, Xiao BH, An LY, Zheng SY, Qi YX, Sun DL. Systematic appraisal of guidelines for the diagnosis of pancreatic cancer. Gland Surg 2021;10:1487-98. [PMID: 33968700 DOI: 10.21037/gs-20-676] [Reference Citation Analysis]
10 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
11 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Reference Citation Analysis]
12 Byrling J, Hilmersson KS, Ansari D, Andersson R, Andersson B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol 2021. [PMID: 34319497 DOI: 10.1007/s12094-021-02685-8] [Reference Citation Analysis]
13 Assenat E, de la Fouchardière C, Portales F, Ychou M, Debourdeau A, Desseigne F, Iltache S, Fiess C, Mollevi C, Mazard T. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial. ESMO Open 2021;6:100318. [PMID: 34837745 DOI: 10.1016/j.esmoop.2021.100318] [Reference Citation Analysis]
14 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Gutiérrez UC, Sánchez-García Ramos E, Domínguez Rosado I, Chan Núñez LC. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev Gastroenterol Mex (Engl Ed) 2021;86:118-24. [PMID: 32616358 DOI: 10.1016/j.rgmx.2020.04.004] [Reference Citation Analysis]
16 Hodolic M, Wu WY, Zhao Z, Yu F, Virgolini I, Wang F. Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use. Eur J Nucl Med Mol Imaging 2021;48:1229-34. [PMID: 33006657 DOI: 10.1007/s00259-020-05045-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tiffon C. Defining Parallels between the Salivary Glands and Pancreas to Better Understand Pancreatic Carcinogenesis. Biomedicines 2020;8:E178. [PMID: 32604970 DOI: 10.3390/biomedicines8060178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Dotz V, Wuhrer M. Histo-blood group glycans in the context of personalized medicine. Biochim Biophys Acta 2016;1860:1596-607. [PMID: 26748235 DOI: 10.1016/j.bbagen.2015.12.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
19 Bourdi M, Rudloff U, Patnaik S, Marugan J, Terse PS. Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells. Regul Toxicol Pharmacol 2020;116:104716. [PMID: 32619635 DOI: 10.1016/j.yrtph.2020.104716] [Reference Citation Analysis]
20 Schlick K, Kiem D, Huemer F, Neureiter D, Weiss L, Greil R. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Technol Cancer Res Treat 2021;20:15330338211042139. [PMID: 34595977 DOI: 10.1177/15330338211042139] [Reference Citation Analysis]
21 Damm M, Weniger M, Kölsch A, Lampert C, Ceyhan GO, Beer S, Schorn S, Moir J, Michl P, Rosendahl J. The quality of pain management in pancreatic cancer: A prospective multi-center study. Pancreatology 2020;20:1511-8. [DOI: 10.1016/j.pan.2020.08.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Moradi F, Iagaru A. The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.Semin Nucl Med. 2020;50:434-446. [PMID: 32768007 DOI: 10.1053/j.semnuclmed.2020.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Purnak T, El Hajj II, Sherman S, Fogel EL, McHenry L, Lehman G, Gromski MA, Al-Haddad M, DeWitt J, Watkins JL, Easler JJ. Combined Versus Separate Sessions of Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for the Diagnosis and Management of Pancreatic Ductal Adenocarcinoma with Biliary Obstruction. Dig Dis Sci 2021;66:2786-94. [PMID: 32852695 DOI: 10.1007/s10620-020-06564-0] [Reference Citation Analysis]
24 Jiang Y, Su Y, Chen Y, Li Z. Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis. J Cancer 2017;8:2765-73. [PMID: 28928865 DOI: 10.7150/jca.19515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol 2019;10:427-35. [PMID: 30842038 DOI: 10.1016/j.jgo.2019.02.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Shekarriz J, Keck T, Shekarriz H. Computerized Medical Evidence-Based Decision Assistance System "MEBDAS®" improves in-hospital outcome after pancreatoduodenectomy for pancreatic cancer. Pancreatology 2020;20:746-50. [PMID: 32312611 DOI: 10.1016/j.pan.2020.04.007] [Reference Citation Analysis]
27 Hua J, Zhang B, Xu J, Liu J, Ni Q, He J, Zheng L, Yu X, Shi S. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. Eur J Surg Oncol 2019;45:1069-76. [PMID: 30685327 DOI: 10.1016/j.ejso.2019.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Farooqui W, Penninga L, Burgdorf SK, Storkholm JH, Hansen CP. Biliary Leakage Following Pancreatoduodenectomy: Experience from a High-Volume Center. J Pancreat Cancer 2021;7:80-5. [PMID: 35024543 DOI: 10.1089/pancan.2021.0014] [Reference Citation Analysis]
29 Ahola R, Siiki A, Vasama K, Vornanen M, Sand J, Laukkarinen J. Patients with resected, histologically re-confirmed pancreatic ductal adenocarcinoma (PDAC) can achieve long-term survival despite T3 tumour or nodal involvement. The Finnish Register Study 2000–2013. Pancreatology 2017;17:822-6. [DOI: 10.1016/j.pan.2017.07.192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Schawkat K, Manning MA, Glickman JN, Mortele KJ. Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils. Radiographics 2020;40:1219-39. [PMID: 32678699 DOI: 10.1148/rg.2020190184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kaech M, Deutschmann E, Moffa G, Haak F, Bucher HC, Kettelhack C, von Strauss Und Torney M. Influence of the introduction of caseload requirements on indication for visceral cancer surgery in Switzerland. Eur J Surg Oncol 2021;47:1324-31. [PMID: 33895025 DOI: 10.1016/j.ejso.2021.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
33 Fu L, Cheng A, Wang X, Fu J, Jin L. 18F-FDG PET/CT in the Detection of Undifferentiated Carcinoma With Osteoclast-like Giant Cells of the Pancreas. Clinical Nuclear Medicine 2017;42:615-6. [DOI: 10.1097/rlu.0000000000001719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, Jamieson NB, Lamarca A, van Santvoort HC, Molenaar IQ, Valle JW, Roberts KJ. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021;47:2248-55. [PMID: 34034941 DOI: 10.1016/j.ejso.2021.04.031] [Reference Citation Analysis]
35 Ma KW, Chan ACY, She WH, Chok KSH, Dai WC, Tsang S, Cheung TT, Lo CM. Efficacy of endoscopic self-expandable metal stent placement versus surgical bypass for inoperable pancreatic cancer-related malignant biliary obstruction: a propensity score-matched analysis. Surg Endosc 2018;32:971-6. [DOI: 10.1007/s00464-017-5774-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Santos I, Mendes L, Mansinho H, Santos CA. Nutritional status and functional status of the pancreatic cancer patients and the impact of adjacent symptoms. Clin Nutr 2021;40:5486-93. [PMID: 34656030 DOI: 10.1016/j.clnu.2021.09.019] [Reference Citation Analysis]
37 Hsu MY, Pan KT, Chen CM, Lui KW, Chu SY, Lin YY, Hung CF, Huang YT, Tseng JH. CT-guided percutaneous core-needle biopsy of pancreatic masses: comparison of the standard mesenteric/retroperitoneal versus the trans-organ approaches. Clin Radiol. 2016;71:507-512. [PMID: 27040800 DOI: 10.1016/j.crad.2016.02.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
38 Morita Y, Sakaguchi T, Kitajima R, Furuhashi S, Kiuchi R, Takeda M, Hiraide T, Shibasaki Y, Kikuchi H, Konno H, Takeuchi H. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. BMC Cancer 2019;19:416. [PMID: 31046709 DOI: 10.1186/s12885-019-5621-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Grenacher L, Juchems M, Schreyer AG, Wessling J, Ringe KI, Uhl W, Mayerle J, Seufferlein T. Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie. Chirurg. [DOI: 10.1007/s00104-022-01617-8] [Reference Citation Analysis]
40 Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. PLoS One 2019;14:e0215915. [PMID: 31059520 DOI: 10.1371/journal.pone.0215915] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
41 Costa B, Estrada MF, Barroso MT, Fior R. Zebrafish Patient‐Derived Avatars from Digestive Cancers for Anti‐cancer Therapy Screening. Current Protocols 2022;2. [DOI: 10.1002/cpz1.415] [Reference Citation Analysis]
42 Ladekarl M, Rasmussen LS, Kirkegård J, Chen I, Pfeiffer P, Weber B, Skuladottir H, Østerlind K, Larsen JS, Mortensen FV, Engberg H, Møller H, Fristrup CW. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Acta Oncol 2021;:1-9. [PMID: 34879787 DOI: 10.1080/0284186X.2021.2012252] [Reference Citation Analysis]
43 Conti G, Pitea M, Ossanna R, Opri R, Tisci G, Falvo E, Innamorati G, Ghanem E, Sbarbati A, Ceci P, Fracasso G. Mitoxantrone-Loaded Nanoferritin Slows Tumor Growth and Improves the Overall Survival Rate in a Subcutaneous Pancreatic Cancer Mouse Model. Biomedicines 2021;9:1622. [PMID: 34829851 DOI: 10.3390/biomedicines9111622] [Reference Citation Analysis]
44 Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:128-38. [PMID: 33338442 DOI: 10.1016/S2468-1253(20)30330-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
45 Alabousi M, McInnes MD, Salameh JP, Satkunasingham J, Kagoma YK, Ruo L, Meyers BM, Aziz T, van der Pol CB. MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma: A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis. J Magn Reson Imaging 2021;53:38-48. [PMID: 31943576 DOI: 10.1002/jmri.27056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
46 Torres SM, Vaz da Silva DG, Ribeiro HSC, Diniz AL, Lobo MM, de Godoy AL, de Farias IC, da Costa WL Jr, de Jesus VHF, Coimbra FJF. Short-term outcomes after vascular resection for pancreatic tumors: Lessons learned from 72 cases from a single Brazilian Cancer Center. J Surg Oncol 2020;121:857-62. [PMID: 31808559 DOI: 10.1002/jso.25799] [Reference Citation Analysis]
47 Kang MJ, Kim SW. Current status and perspectives of the future of pancreatic surgery: Establishment of evidence by integration of "art" and "science". Ann Gastroenterol Surg 2021;5:738-46. [PMID: 34755005 DOI: 10.1002/ags3.12494] [Reference Citation Analysis]
48 Kim SS, Lee S, Lee HS, Bang S, Park MS. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol (NY) 2021;46:655-66. [PMID: 32748250 DOI: 10.1007/s00261-020-02661-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Marinelli V, Danzi OP, Mazzi MA, Secchettin E, Tuveri M, Bonamini D, Rimondini M, Salvia R, Bassi C, Del Piccolo L. PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic Cancer Patients Prior to Major Surgery. Front Psychol 2020;11:362. [PMID: 32194490 DOI: 10.3389/fpsyg.2020.00362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
50 Anger F, Döring A, Schützler J, Germer CT, Kunzmann V, Schlegel N, Lock JF, Wiegering A, Löb S, Klein I. Prognostic impact of simultaneous venous resections during surgery for resectable pancreatic cancer. HPB (Oxford) 2020;22:1384-93. [PMID: 31980308 DOI: 10.1016/j.hpb.2019.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Catanese S, Pentheroudakis G, Douillard JY, Lordick F. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open. 2020;5. [PMID: 32423899 DOI: 10.1136/esmoopen-2020-000804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
52 Faleiro I, Roberto VP, Demirkol Canli S, Fraunhoffer NA, Iovanna J, Gure AO, Link W, Castelo-branco P. DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers 2021;13:6354. [DOI: 10.3390/cancers13246354] [Reference Citation Analysis]
53 Rossi E, Bagalà C, Inzani F, Leoncini E, Brunelli C, Lanza P, Basso M, Mattiucci GC, Cassano A, Rindi G, Barone C, Schinzari G. RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. In Vivo 2017;31:833-40. [PMID: 28882948 DOI: 10.21873/invivo.11136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
55 Dhayat SA, Mirgorod P, Lenschow C, Senninger N, Anthoni C, Vowinkel T. Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines. PLoS One 2017;12:e0173374. [PMID: 28267771 DOI: 10.1371/journal.pone.0173374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Heger U, Hackert T. Can local ablative techniques replace surgery for locally advanced pancreatic cancer? J Gastrointest Oncol 2021;12:2536-46. [PMID: 34790414 DOI: 10.21037/jgo-20-379] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Guerard A, Ayav A, Busby H, Lafitte M, Rousseau H, Laurent V. Early liver metastases in resectable periampullary cancer: Incidence and risk factors. European Journal of Radiology 2017;93:265-72. [DOI: 10.1016/j.ejrad.2017.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Chen Q, Yuan H, Shi GD, Wu Y, Liu DF, Lin YT, Chen L, Ge WL, Jiang K, Miao Y. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Onco Targets Ther 2018;11:2709-23. [PMID: 29785120 DOI: 10.2147/OTT.S157759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
59 Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 [PMID: 30595804 DOI: 10.4251/wjgo.v10.i12.505] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
60 Tonneau M, Lacornerie T, Mirabel X, Pasquier D. [Stereotactic body radiotherapy for locally advanced pancreatic cancer: A systemic review]. Cancer Radiother 2021;25:283-95. [PMID: 33423968 DOI: 10.1016/j.canrad.2020.08.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Huang Y, Zhu N, Zheng X, Liu Y, Lu H, Yin X, Hao H, Tan Y, Wang D, Hu H, Liang Y, Li X, Hu Z, Yin Y. Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas. Front Immunol 2022;13:785422. [DOI: 10.3389/fimmu.2022.785422] [Reference Citation Analysis]
62 Faron M, Laas E. [Does sentinel lymph node identification has indication in digestive cancers?]. Bull Cancer 2020;107:660-5. [PMID: 31627907 DOI: 10.1016/j.bulcan.2019.06.013] [Reference Citation Analysis]
63 Hecht EM, Zins M, Tamm EP. Editorial for "MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma: A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis". J Magn Reson Imaging 2021;53:49-50. [PMID: 32034836 DOI: 10.1002/jmri.27072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Fernandez-Rozadilla C, Simões AR, Lleonart ME, Carnero A, Carracedo Á. Tumor Profiling at the Service of Cancer Therapy. Front Oncol 2020;10:595613. [PMID: 33505911 DOI: 10.3389/fonc.2020.595613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
65 Groen JV, Sibinga Mulder BG, van Eycken E, Valerianova Z, Borras JM, van der Geest LGM, Capretti G, Schlesinger-Raab A, Primic-Zakelj M, Ryzhov A, van de Velde CJH, Bonsing BA, Bastiaannet E, Mieog JSD. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Ann Surg Oncol 2018;25:3492-501. [PMID: 30151560 DOI: 10.1245/s10434-018-6705-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. Eur J Cancer 2018;105:71-8. [PMID: 30414528 DOI: 10.1016/j.ejca.2018.09.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
67 Giovinazzo F, Soggiu F, Jang JY, Versteijne E, van Tienhoven G, van Eijck CH, Han Y, Choi SH, Kang CM, Zalupski M, Ahmad H, Yentz S, Helton S, Rose JB, Takishita C, Nagakawa Y, Abu Hilal M. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.Front Oncol. 2020;10:1112. [PMID: 32850319 DOI: 10.3389/fonc.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, Wilthoner K, Sliwa T, Pichler P, Winder T, Heibl S, Gruenberger B, Laengle F, Hubmann E, Korger M, Pecherstorfer M, Djanani A, Neumann HJ, Philipp-Abbrederis K, Wöll E, Trondl R, Arnold-Schrauf C, Eisterer W. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. Eur J Cancer 2021;143:101-12. [PMID: 33296830 DOI: 10.1016/j.ejca.2020.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuño FM, Guillen-Ponce C, Rojas I, Aranda E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLoS One 2018;13:e0194844. [PMID: 29617451 DOI: 10.1371/journal.pone.0194844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
70 Wang Y, Camateros P, Cheung WY. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. J Gastrointest Cancer. 2019;50:62-68. [PMID: 29143916 DOI: 10.1007/s12029-017-0028-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
71 Groen JV, Michiels N, van Roessel S, Besselink MG, Bosscha K, Busch OR, van Dam R, van Eijck CHJ, Koerkamp BG, van der Harst E, de Hingh IH, Karsten TM, Lips DJ, de Meijer VE, Molenaar IQ, Nieuwenhuijs VB, Roos D, van Santvoort HC, Wijsman JH, Wit F, Zonderhuis BM, de Vos-Geelen J, Wasser MN, Bonsing BA, Stommel MWJ, Mieog JSD; Dutch Pancreatic Cancer Group. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Br J Surg 2021:znab345. [PMID: 34791069 DOI: 10.1093/bjs/znab345] [Reference Citation Analysis]
72 Shi CJ, Zhao Y, Wang M, Tian R, Li X, Guo XJ, Peng F, Zhang H, Feng YC, Qin RY. Clinical significance of expression of olfactory receptor family 2 subfamily W member 3 in human pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(20): 1229-1233 [DOI: 10.11569/wcjd.v26.i20.1229] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Qu C, Zeng P, Wang H, Yuan C, Yuan H, Xiu D. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Magnetic Resonance Imaging. [DOI: 10.1002/jmri.28096] [Reference Citation Analysis]
74 Lok HT, Fung AKY, Chong CCN, Lee KF, Wong J, Cheung SYS, Lai PBS, Ng KKC. Comparison of long-term survival outcome after curative hepatectomy between selected patients with non-colorectal and colorectal liver metastasis: A propensity score matching analysis. Asian J Surg 2021;44:459-64. [PMID: 33229125 DOI: 10.1016/j.asjsur.2020.10.019] [Reference Citation Analysis]
75 van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, Lemmens VEPP, Busch OR, Vissers PAJ, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med 2018;7:4943-51. [PMID: 30188015 DOI: 10.1002/cam4.1750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
76 Huang BZ, Pandol SJ, Jeon CY, Chari ST, Sugar CA, Chao CR, Zhang ZF, Wu BU, Setiawan VW. New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population. Clin Gastroenterol Hepatol 2020;18:1812-1821.e7. [PMID: 31809917 DOI: 10.1016/j.cgh.2019.11.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
77 Kwon W, Thomas A, Kluger MD. Irreversible electroporation of locally advanced pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00009-9. [PMID: 33648735 DOI: 10.1053/j.seminoncol.2021.02.004] [Reference Citation Analysis]
78 Chen B, Hu C, Jiang L, Xiang Z, Zuo Z, Lin Y, Liu C. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. Int Immunopharmacol 2021;92:107359. [PMID: 33465729 DOI: 10.1016/j.intimp.2020.107359] [Reference Citation Analysis]
79 Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019;11:1758835919850367. [PMID: 31205510 DOI: 10.1177/1758835919850367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
80 Chen F, Zhou Y, Qi X, Xia W, Zhang R, Zhang J, Gao X, Zhang L. CT texture analysis for the presurgical prediction of superior mesenteric-portal vein invasion in pancreatic ductal adenocarcinoma: comparison with CT imaging features. Clin Radiol 2021;76:358-66. [PMID: 33581837 DOI: 10.1016/j.crad.2021.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. J Nucl Med 2018;59:809-14. [PMID: 29025990 DOI: 10.2967/jnumed.117.193847] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
82 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Dengsø KE, Thomsen T, Andersen EW, Hansen CP, Christensen BM, Hillingsø J, Dalton SO. The psychological symptom burden in partners of pancreatic cancer patients: a population-based cohort study. Support Care Cancer 2021. [PMID: 33963908 DOI: 10.1007/s00520-021-06251-4] [Reference Citation Analysis]
84 Serikuly E, Makhanbetkhan SS, Baymakhanov ZB, Kaniev SA, Doskhanov MO, Chormanov AT, Seysembaev MA, Baymakhanov BB. [Comparative analysis of radical surgical treatment of periampullary tumors]. Khirurgiia (Mosk) 2020;:24-9. [PMID: 32352664 DOI: 10.17116/hirurgia202004124] [Reference Citation Analysis]
85 Dengsø KE, Andersen EW, Thomsen T, Hansen CP, Christensen BM, Hillingsø J, Dalton SO. Increased psychological symptom burden in patients with pancreatic cancer: A population-based cohort study. Pancreatology 2020;20:511-21. [PMID: 31973981 DOI: 10.1016/j.pan.2020.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Fernandez Y Viesca M, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. Clin Exp Gastroenterol. 2019;12:415-432. [PMID: 31807048 DOI: 10.2147/ceg.s195714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
87 Templeton S, Moser M, Wall C, Shaw J, Chalchal H, Luo Y, Zaidi A, Ahmed S. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. J Gastrointest Cancer 2021;52:529-35. [PMID: 32440849 DOI: 10.1007/s12029-020-00417-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Maharaj AD, Ioannou L, Croagh D, Zalcberg J, Neale RE, Goldstein D, Merrett N, Kench JG, White K, Pilgrim CH, Chantrill L, Cosman P, Kneebone A, Lipton L, Nikfarjam M, Philip J, Sandroussi C, Tagkalidis P, Chye R, Haghighi KS, Samra J, Evans SM. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. HPB 2019;21:444-55. [DOI: 10.1016/j.hpb.2018.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
89 Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020;22:1963-75. [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
91 Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol 2016;18:1172-8. [PMID: 27896637 DOI: 10.1007/s12094-016-1586-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
92 Zlobec I, Berger MD, Lugli A. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer 2020;123:700-8. [PMID: 32601463 DOI: 10.1038/s41416-020-0954-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
93 Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018;287:374-390. [PMID: 29668413 DOI: 10.1148/radiol.2018171670] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
94 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
95 Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology 2021;21:192-9. [PMID: 33214082 DOI: 10.1016/j.pan.2020.10.029] [Reference Citation Analysis]
96 Wong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy: an editorial comment. Ann Transl Med 2019;7:S26. [PMID: 31032306 DOI: 10.21037/atm.2019.01.75] [Reference Citation Analysis]
97 Jimenez-Luna C, Torres C, Ortiz R, Dieguez C, Martinez-Galan J, Melguizo C, Prados JC, Caba O. Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget. 2018;9:16573-16587. [PMID: 29662668 DOI: 10.18632/oncotarget.24654] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
98 Sauter M, Vavricka SR, Keilholz G, Heinrich H, Winder T, Kranzbühler H, Lombriser N, Misselwitz B. Surveillance of anal carcinoma after radiochemotherapy: A retrospective analysis of 80 patients. Strahlenther Onkol 2017;193:639-47. [DOI: 10.1007/s00066-017-1159-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Martinez-useros J, Li W, Georgiev-hristov T, Fernandez-aceñero MJ, Borrero-palacios A, Perez N, Celdran A, Garcia-foncillas J. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathol Oncol Res 2019;25:269-78. [DOI: 10.1007/s12253-017-0341-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Grillo F, Ferro J, Vanoli A, Delfanti S, Pitto F, Peñuela L, Bianchi R, Grami O, Fiocca R, Mastracci L. Comparison of pathology sampling protocols for pancreatoduodenectomy specimens. Virchows Arch 2020;476:735-44. [PMID: 31802231 DOI: 10.1007/s00428-019-02687-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Zhang X, Fan H, Kou J, Zhang X, Li P, Dai Y, He Q. Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer: Venous resection and reconstruction. Journal of Gastroenterology and Hepatology 2016;31:1498-503. [DOI: 10.1111/jgh.13299] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
102 Blouhos K, Boulas K, Tsalis K, Hatzigeorgiadis A. The isoattenuating pancreatic adenocarcinoma: Review of the literature and critical analysis. Surgical Oncology 2015;24:322-8. [DOI: 10.1016/j.suronc.2015.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
103 Schorr F, Essig MW. [Early detection of pancreatic cancer - The role of endoscopic and transabdominal ultrasound]. Z Gastroenterol 2021. [PMID: 34243212 DOI: 10.1055/a-1515-3123] [Reference Citation Analysis]
104 Mai S, Inkielewicz-Stepniak I. Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target. Front Cell Dev Biol 2021;9:749689. [PMID: 34858977 DOI: 10.3389/fcell.2021.749689] [Reference Citation Analysis]
105 Hwang JS, Joo HD, Song TJ. Endoscopic Ultrasound-Guided Local Therapy for Pancreatic Neoplasms. Clin Endosc 2020;53:535-40. [PMID: 33027583 DOI: 10.5946/ce.2020.181] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Selleck MJ, Senthil M, Wall NR. Making Meaningful Clinical Use of Biomarkers. Biomark Insights. 2017;12:1177271917715236. [PMID: 28659713 DOI: 10.1177/1177271917715236] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
107 Pentheroudakis G; ESMO Guidelines Committee. Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol 2019;30:1395-7. [PMID: 31168599 DOI: 10.1093/annonc/mdz180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
108 European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789-804. [PMID: 29574408 DOI: 10.1136/gutjnl-2018-316027] [Cited by in Crossref: 380] [Cited by in F6Publishing: 283] [Article Influence: 95.0] [Reference Citation Analysis]
109 Geers J, Topal H, Jaekers J, Topal B. 3D-laparoscopic pancreaticoduodenectomy with superior mesenteric or portal vein resection for pancreatic cancer. Surg Endosc 2020;34:5616-24. [PMID: 32749613 DOI: 10.1007/s00464-020-07847-3] [Reference Citation Analysis]
110 Cascinu S, Berardi R, Bianco R, Bilancia D, Zaniboni A, Ferrari D, Mosconi S, Spallanzani A, Cavanna L, Leo S, Negri F, Beretta GD, Sobrero A, Banzi M, Morabito A, Bittoni A, Marciano R, Ferrara D, Noventa S, Piccirillo MC, Labianca R, Mosconi C, Casadei Gardini A, Gallo C, Perrone F. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial. Eur J Cancer 2021;148:422-9. [PMID: 33812334 DOI: 10.1016/j.ejca.2021.02.023] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Belyaev O, Bösch F, Brunner M, Müller-debus CF, Radulova-mauersberger O, Wellner UF, Grützmann R, Keck T, Werner J, Witzigmann H, Uhl W. Von der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie konsentierte Operationsindikationen beim duktalen Pankreasadenokarzinom. Zentralbl Chir 2020;145:354-64. [DOI: 10.1055/a-1161-9501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O’Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019; 11(2): 102-116 [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
113 Olson JL, Bold RJ. Currently available first-line drug therapies for treating pancreatic cancer. Expert Opin Pharmacother 2018;19:1927-40. [PMID: 30325679 DOI: 10.1080/14656566.2018.1509954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Malvi D, Vasuri F, Maloberti T, Sanza V, De Leo A, Fornelli A, Masetti M, Benini C, Lombardi R, Offi MF, Di Marco M, Ravaioli M, Fiorino S, Franceschi E, Brandes AA, Jovine E, D’errico A, Tallini G, de Biase D. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics 2022;12:1058. [DOI: 10.3390/diagnostics12051058] [Reference Citation Analysis]
115 Kamposioras K, Tsimplouli C, Verbeke C, Anthoney A, Daoukopoulou A, Papandreou CN, Sakellaridis N, Vassilopoulos G, Potamianos SP, Liakouli V, Migneco G, Del Galdo F, Dimas K. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. Int J Oncol 2019;54:537-49. [PMID: 30483772 DOI: 10.3892/ijo.2018.4640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
116 Mueller AM, Meier CR, Jick SS, Schneider C. Weight change and blood glucose concentration as markers for pancreatic cancer in subjects with new-onset diabetes mellitus: A matched case-control study. Pancreatology 2019;19:578-86. [PMID: 30952448 DOI: 10.1016/j.pan.2019.03.006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
117 Alberghina N, Sánchez-Montes C, Tuñón C, Maurel J, Araujo IK, Ferrer J, Sendino O, Córdova H, Vaquero EC, González-Suárez B, Martínez-Palli G, Ginès À, Fernández-Esparrach G. Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis. Pancreatology 2017;17:858-64. [PMID: 28844696 DOI: 10.1016/j.pan.2017.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
118 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
119 Picozzi V, Narayanan S, Henry Hu X, Vacirca J. Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. J Gastrointest Canc 2017;48:103-9. [DOI: 10.1007/s12029-016-9902-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
120 Yang X, Guo JF, Sun LQ, Hu JH, Shi YJ, Zhang JY, Jin ZD. Assessment of different modalities for repeated tissue acquisition in diagnosing malignant biliary strictures: A two-center retrospective study. J Dig Dis 2021;22:102-7. [PMID: 33247545 DOI: 10.1111/1751-2980.12964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Védie A, Neuzillet C. Pancreatic cancer: Best supportive care. La Presse Médicale 2019;48:e175-85. [DOI: 10.1016/j.lpm.2019.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
122 Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med 2020;9:9396-408. [PMID: 33099898 DOI: 10.1002/cam4.3558] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
123 O'Connor D, Brown M, Eatock M, Turkington RC, Prue G. Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review. BMC Cancer 2021;21:43. [PMID: 33422020 DOI: 10.1186/s12885-020-07733-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, Cervantes A. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev 2018;68:124-35. [PMID: 29957372 DOI: 10.1016/j.ctrv.2018.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
125 Sánchez-Bueno F, García-Pérez R, Claver Valderas MA, de la Peña Moral J, Frutos Esteban L, Ortiz Ruiz E, Fuster Quiñonero M, Parrilla Paricio P. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases. Cir Esp 2016;94:511-7. [PMID: 27712835 DOI: 10.1016/j.ciresp.2016.07.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Antonios A, Gharios J, Tohme C. Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care? Future Oncology 2017;13:951-3. [DOI: 10.2217/fon-2017-0050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
127 Wode K, Hök Nordberg J, Kienle GS, Elander NO, Bernhardson BM, Sunde B, Sharp L, Henriksson R, Fransson P. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials 2020;21:783. [PMID: 32917288 DOI: 10.1186/s13063-020-04581-y] [Reference Citation Analysis]
128 Yu J, Yang X, He W, Ye W. Burden of pancreatic cancer along with attributable risk factors in Europe between 1990 and 2019, and projections until 2039. Int J Cancer 2021;149:993-1001. [PMID: 33937984 DOI: 10.1002/ijc.33617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Boeck S. Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opin Investig Drugs 2022. [PMID: 35114868 DOI: 10.1080/13543784.2022.2037552] [Reference Citation Analysis]
130 Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel) 2021;14:740. [PMID: 34451837 DOI: 10.3390/ph14080740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Huang L, Jansen L, Balavarca Y, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Primic-Žakelj M, Zadnik V, Besselink MG, Schrotz-King P, Brenner H. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med 2018;16:125. [PMID: 30126408 DOI: 10.1186/s12916-018-1120-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
132 Seaton M, Hanna A, Boutros C, Hanna N. Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database. Ther Adv Med Oncol 2019;11:1758835919842438. [PMID: 31105777 DOI: 10.1177/1758835919842438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPW, van Santvoort HC, Molenaar IQ. The diagnostic performance of CT vs FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.Eur J Radiol. 2018;106:128-136. [PMID: 30150034 DOI: 10.1016/j.ejrad.2018.07.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
134 Castillo Tuñón JM, Valle Rodas ME, Botello Martínez F, Rojas Holguín A, López Guerra D, Santos Naharro J, Jaén Torrejímeno I, Blanco Fernández G. Implementation of a regional reference center in pancreatic surgery. Experience after 631 procedures. Cir Esp (Engl Ed) 2020:S0009-739X(20)30313-4. [PMID: 33342520 DOI: 10.1016/j.ciresp.2020.09.013] [Reference Citation Analysis]
135 Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treat Rev 2021;99:102208. [PMID: 34238640 DOI: 10.1016/j.ctrv.2021.102208] [Reference Citation Analysis]
136 Langheinrich M, Wirtz S, Kneis B, Gittler MM, Tyc O, Schierwagen R, Brunner M, Krautz C, Weber GF, Pilarsky C, Trebicka J, Agaimy A, Grützmann R, Kersting S. Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. J Clin Med 2020;9:E2785. [PMID: 32872220 DOI: 10.3390/jcm9092785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 BarrÈre APN, Piovacari SMF, UsÓn Junior PLS, Gansl RC, Pereira AZ, Hamerschlak N. BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY. Arq Gastroenterol 2020;57:278-82. [PMID: 33027479 DOI: 10.1590/S0004-2803.202000000-52] [Reference Citation Analysis]
138 Cortesi M, Zamagni A, Pignatta S, Zanoni M, Arienti C, Rossi D, Collina S, Tesei A. Pan-Sigma Receptor Modulator RC-106 Induces Terminal Unfolded Protein Response In In Vitro Pancreatic Cancer Model. Int J Mol Sci 2020;21:E9012. [PMID: 33260926 DOI: 10.3390/ijms21239012] [Reference Citation Analysis]
139 Gao Z, Wu J, Wu X, Zheng J, Ou Y. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis. Open Med (Wars) 2020;15:1072-82. [PMID: 33336063 DOI: 10.1515/med-2020-0157] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
140 Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo 2018;32:653-7. [PMID: 29695574 DOI: 10.21873/invivo.11289] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
141 Flak RV, Stender MT, Jensen TM, Andersen KL, Henriksen SD, Mortensen PB, Sall M, Thorlacius-Ussing O. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. Scand J Gastroenterol. 2019;54:252-258. [PMID: 30907286 DOI: 10.1080/00365521.2019.1575465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
142 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
143 Lee JC, Ahn S, Cho IK, Lee J, Kim J, Hwang JH. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. BMJ Open 2018;8:e017249. [PMID: 29632079 DOI: 10.1136/bmjopen-2017-017249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
144 Chin YK, Iglesias-Garcia J, de la Iglesia D, Lariño-Noia J, Abdulkader-Nallib I, Lázare H, Rebolledo Olmedo S, Dominguez-Muñoz JE. Accuracy of endoscopic ultrasound-guided tissue acquisition in the evaluation of lymph nodes enlargement in the absence of on-site pathologist. World J Gastroenterol 2017; 23(31): 5755-5763 [PMID: 28883701 DOI: 10.3748/wjg.v23.i31.5755] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
145 Maharaj AD, Holland JF, Scarborough RO, Evans SM, Ioannou LJ, Brown W, Croagh DG, Pilgrim CHC, Kench JG, Lipton LR, Leong T, McNeil JJ, Nikfarjam M, Aly A, Burton PR, Cashin PA, Chu J, Duong CP, Evans P, Goldstein D, Haydon A, Hii MW, Knowles BPF, Merrett ND, Michael M, Neale RE, Philip J, Porter IWT, Smith M, Spillane J, Tagkalidis PP, Zalcberg JR. The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. BMJ Open 2019;9:e031434. [PMID: 31575580 DOI: 10.1136/bmjopen-2019-031434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
146 Ahola R, Siiki A, Vasama K, Vornanen M, Sand J, Laukkarinen J. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Br J Surg. 2017;104:1532-1538. [PMID: 28517236 DOI: 10.1002/bjs.10560] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
147 Zhou Q, Andersson R, Hu D, Bauden M, Sasor A, Bygott T, PawŁowski K, Pla I, Marko-Varga G, Ansari D. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Transl Res 2019;212:67-79. [PMID: 31295437 DOI: 10.1016/j.trsl.2019.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
148 Williet N, Petrillo A, Roth G, Ghidini M, Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F, Taieb J, Phelip JM. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers (Basel) 2021;13:2797. [PMID: 34199796 DOI: 10.3390/cancers13112797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
149 Bultmann U, Niedergethmann M, Gelos M. Postoperative results, pathologic outcome, and long-term patency rate of autologous vein reconstruction of the mesentericoportal axis after pancreatectomy. Langenbecks Arch Surg 2021;406:1453-60. [DOI: 10.1007/s00423-020-02026-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Luijten JCHBM, Nieuwenhuijzen GAP, Sosef MN, de Hingh IHJT, Rosman C, Ruurda JP, van Duijvendijk P, Heisterkamp J, de Steur WO, van Laarhoven HWM, Besselink MG, Groot Koerkamp B, van Santvoort HC, Lemmens VEP, Vissers PAJ. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. Eur J Surg Oncol 2021:S0748-7983(21)00645-4. [PMID: 34366174 DOI: 10.1016/j.ejso.2021.07.023] [Reference Citation Analysis]
151 Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Vissers PA, Zadnik V, Brenner H. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol 2018;10:1109-25. [PMID: 30214315 DOI: 10.2147/CLEP.S160973] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
152 Frampton JE. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs 2020;80:1007-18. [PMID: 32557396 DOI: 10.1007/s40265-020-01336-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
153 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
154 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
155 Pang HYM, Chalmers K, Landon B, Elshaug AG, Matelski J, Ling V, Krzyzanowska MK, Kulkarni G, Erickson BA, Cram P. Utilization Rates of Pancreatectomy, Radical Prostatectomy, and Nephrectomy in New York, Ontario, and New South Wales, 2011 to 2018. JAMA Netw Open 2021;4:e215477. [PMID: 33871618 DOI: 10.1001/jamanetworkopen.2021.5477] [Reference Citation Analysis]
156 Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Ishimoto U, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, Hiraoka N. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Br J Cancer 2021. [PMID: 34824448 DOI: 10.1038/s41416-021-01639-9] [Reference Citation Analysis]
157 Björkman K, Mustonen H, Kaprio T, Kekki H, Pettersson K, Haglund C, Böckelman C. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. Tumour Biol 2021;43:57-70. [PMID: 33935125 DOI: 10.3233/TUB-200069] [Reference Citation Analysis]
158 Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol 2019;31:346-53. [PMID: 30994497 DOI: 10.1097/CCO.0000000000000546] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
159 Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang HM, Oh D, Song TJ, Park DH, Lee SS, Lee SK, Kim MH, Park JH, Kim KP, Ryoo BY. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat. 2020;52:254-262. [PMID: 31291709 DOI: 10.4143/crt.2019.190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
160 Roeyen G, Berrevoet F, Borbath I, Geboes K, Peeters M, Topal B, Van Cutsem E, Van Laethem J. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open 2022;7:100386. [DOI: 10.1016/j.esmoop.2022.100386] [Reference Citation Analysis]
161 Elberg Dengsø K, Tjørnhøj-Thomsen T, Oksbjerg Dalton S, Marcel Christensen B, Hillingsø J, Thomsen T. It's all about the CA-19-9. A longitudinal qualitative study of patients' experiences and perspectives on follow-up after curative surgery for cancer in the pancreas, duodenum or bile-duct. Acta Oncol 2019;58:642-9. [PMID: 30698053 DOI: 10.1080/0284186X.2018.1562212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
162 Capurso G, Archibugi L, Petrone MC, Arcidiacono PG. Slow-pull compared to suction technique for EUS-guided sampling of pancreatic solid lesions: a meta-analysis of randomized controlled trials. Endosc Int Open 2020;8:E636-43. [PMID: 32355882 DOI: 10.1055/a-1120-8428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
163 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
164 Ghidini M, Vuozzo M, Galassi B, Mapelli P, Ceccarossi V, Caccamo L, Picchio M, Dondossola D. The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic Cancer. Cancers (Basel) 2021;13:4155. [PMID: 34439307 DOI: 10.3390/cancers13164155] [Reference Citation Analysis]
165 O'Reilly EM, Cockrum P, Surinach A, Wu Z, Dillon A, Yu KH. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Cancer Med. 2020;9:8480-8490. [PMID: 32997898 DOI: 10.1002/cam4.3477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
166 Driescher C, Fuchs K, Haeberle L, Goering W, Frohn L, Opitz FV, Haeussinger D, Knoefel WT, Keitel V, Esposito I. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers (Basel) 2020;13:E39. [PMID: 33375555 DOI: 10.3390/cancers13010039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Xu S, Zhang XJ, Guan LJ, Li B, Wang L, Li XG. Proton Pump Inhibitors Increase the Risk of Early Biliary Infection After Placement of Percutaneous Transhepatic Biliary Stents. J Vasc Interv Radiol 2021;32:569-75. [PMID: 33461872 DOI: 10.1016/j.jvir.2020.12.020] [Reference Citation Analysis]
168 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
169 Zechner D, Bürtin F, Albert AC, Zhang X, Kumstel S, Schönrogge M, Graffunder J, Shih HY, Müller S, Radecke T, Jaster R, Vollmar B. Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget 2016;7:56395-407. [PMID: 27486761 DOI: 10.18632/oncotarget.10892] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
170 de la Pinta C. Radiomics in pancreatic cancer for oncologist: Present and future. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00231-9. [PMID: 34961674 DOI: 10.1016/j.hbpd.2021.12.006] [Reference Citation Analysis]
171 Acu B, Kurtulus Ozturk E. Feasibility and safety of percutaneous transhepatic endobiliary radiofrequency ablation as an adjunct to biliary stenting in malignant biliary obstruction. Diagnostic and Interventional Imaging 2018;99:237-45. [DOI: 10.1016/j.diii.2017.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
172 Bittoni A, Pecci F, Mentrasti G, Crocetti S, Lupi A, Lanese A, Pellei C, Ciotti C, Cantini L, Giampieri R, Lenci E, Giglio E, Bini F, Copparoni C, Meletani T, Baleani MG, Berardi R. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Ann Transl Med 2021;9:251. [PMID: 33708878 DOI: 10.21037/atm-20-3499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Michalski CW, Liu B, Heckler M, Roth S, Sun H, Heger U, Büchler MW, Hackert T. Underutilization of Surgery in Periampullary Cancer Treatment. J Gastrointest Surg 2019;23:959-65. [PMID: 30088190 DOI: 10.1007/s11605-018-3897-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol 2020;17:940-53. [PMID: 32699350 DOI: 10.1038/s41423-020-0505-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
175 Flak RV, Stender MT, Stenholt L, Thorlacius-Ussing O, Petersen LJ. Imaging response evaluation after local ablative treatments in locally advanced pancreatic cancer: an expedited systematic review. HPB (Oxford) 2020;22:1083-91. [PMID: 32451236 DOI: 10.1016/j.hpb.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Tumas J, Kvederaviciute K, Petrulionis M, Kurlinkus B, Rimkus A, Sakalauskaite G, Cicenas J, Sileikis A. Metabolomics in pancreatic cancer biomarkers research. Med Oncol 2016;33:133. [PMID: 27807722 DOI: 10.1007/s12032-016-0853-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
177 Yu KH, Ozer M, Cockrum P, Surinach A, Wang S, Chu BC. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med 2021;10:8934-43. [PMID: 34811961 DOI: 10.1002/cam4.4415] [Reference Citation Analysis]
178 Wang M, Xu Y, Yang M, Jiang D, Chen Y, Jiang J, Chen Z, Yang L, Huang D. Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review. Front Pharmacol 2020;11:579239. [PMID: 33117173 DOI: 10.3389/fphar.2020.579239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, Alcindor T, Potvin D, Chao R, Hurwitz H. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemother Pharmacol 2018;81:355-64. [PMID: 29238851 DOI: 10.1007/s00280-017-3494-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
180 Yun SJ, Kim SK, Kim J, Cha EJ, Kim JS, Kim SJ, Ha YS, Kim YH, Jeong P, Kang HW, Kim JH, Park JL, Choi YK, Moon SK, Choi YH, Kim SY, Kim WJ. Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer. Oncotarget 2017;8:114845-55. [PMID: 29383125 DOI: 10.18632/oncotarget.22296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
181 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
182 Silvestris N, Falconi M. Focus on pancreatic cancer. Dig Liver Dis 2018;50:1272-3. [PMID: 30301604 DOI: 10.1016/j.dld.2018.09.003] [Reference Citation Analysis]
183 Gérard C, Fagnoni P, Vienot A, Borg C, Limat S, Daval F, Calais F, Vardanega J, Jary M, Nerich V. A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. Eur J Cancer 2017;86:207-16. [PMID: 29024890 DOI: 10.1016/j.ejca.2017.08.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
184 D'Onofrio M, De Robertis R, Aluffi G, Cadore C, Beleù A, Cardobi N, Malleo G, Manfrin E, Bassi C. CT Simplified Radiomic Approach to Assess the Metastatic Ductal Adenocarcinoma of the Pancreas. Cancers (Basel) 2021;13:1843. [PMID: 33924363 DOI: 10.3390/cancers13081843] [Reference Citation Analysis]
185 Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol 2021; 27(21): 2710-2726 [PMID: 34135550 DOI: 10.3748/wjg.v27.i21.2710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Forciniti S, Dalla Pozza E, Greco MR, Amaral Carvalho TM, Rolando B, Ambrosini G, Carmona-Carmona CA, Pacchiana R, Di Molfetta D, Donadelli M, Arpicco S, Palmieri M, Reshkin SJ, Dando I, Cardone RA. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Int J Mol Sci 2020;22:E29. [PMID: 33375106 DOI: 10.3390/ijms22010029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346 [PMID: 32206183 DOI: 10.4251/wjgo.v12.i3.332] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 2020;9:5406-15. [PMID: 32519420 DOI: 10.1002/cam4.3229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
189 Harmsen FR, Domagk D, Dietrich CF, Hocke M. Discriminating chronic pancreatitis from pancreatic cancer: Contrast-enhanced EUS and multidetector computed tomography in direct comparison. Endosc Ultrasound. 2018;7:395-403. [PMID: 30246709 DOI: 10.4103/eus.eus_24_18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
190 Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Onco Targets Ther 2019;12:1455-63. [PMID: 30863113 DOI: 10.2147/OTT.S167590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
191 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
192 Lamb YN, Scott LJ. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs 2017;77:785-92. [PMID: 28401446 DOI: 10.1007/s40265-017-0741-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
193 Liberko M, Kolostova K, Szabo A, Gurlich R, Oliverius M, Soumarova R. Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review. In Vivo 2021;35:31-9. [PMID: 33402447 DOI: 10.21873/invivo.12229] [Reference Citation Analysis]
194 Jäger R, Weigel R, Forthuber B, Ganswindt U. Integrating radiation oncology into the management of pancreatic cancer. Eur Surg 2019;51:139-45. [DOI: 10.1007/s10353-019-0577-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
195 Kim G. nab-Paclitaxel for the treatment of pancreatic cancer. Cancer Manag Res 2017;9:85-96. [PMID: 28356771 DOI: 10.2147/CMAR.S127840] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
196 Tanaka M, Inoue Y, Matsueda K, Hiratsuka M, Muto M, Kawakatsu S, Ono Y, Mise Y, Ishizawa T, Ito H, Takahashi Y, Takazawa Y, Saiura A. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. J Gastrointest Surg 2020;24:619-26. [PMID: 30937709 DOI: 10.1007/s11605-019-04203-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
197 Vera R, Ferrández A, Ferrer CJ, Flores C, Joaquín C, López S, Martín T, Martín E, Marzo M, Sarrión A, Vaquero E, Zapatero A, Aparicio J. Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. Clin Transl Oncol 2017;19:834-43. [PMID: 28105537 DOI: 10.1007/s12094-016-1609-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
198 van Veldhuisen E, Vroomen LG, Ruarus AH, Derksen TC, Busch OR, de Jong MC, Kazemier G, Puijk RS, Sorgedrager NS, Vogel JA, Scheffer HJ, van Lienden KP, Wilmink JW, Besselink MG, Meijerink MR. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. J Vasc Interv Radiol. 2020;31:1600-1608. [PMID: 32861569 DOI: 10.1016/j.jvir.2020.02.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
199 Fancellu A, Petrucciani N, Porcu A, Deiana G, Sanna V, Ninniri C, Perra T, Celoria V, Nigri G. The Impact on Survival and Morbidity of Portal-Mesenteric Resection During Pancreaticoduodenectomy for Pancreatic Head Adenocarcinoma: A Systematic Review and Meta-Analysis of Comparative Studies. Cancers (Basel). 2020;12. [PMID: 32698500 DOI: 10.3390/cancers12071976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
200 Schwartz M, Korenbaum C, Benfoda M, Mary M, Colas C, Coulet F, Parrin M, Jonveaux P, Ingster O, Granier S, De Mestier L, Cros J, Riffault A, Muller M, Levy P, Rebours V, Greenhalf W, Soufir N, Hammel P. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. Clin Genet 2019;96:579-84. [DOI: 10.1111/cge.13629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
201 Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017;46:203-208. [PMID: 27841795 DOI: 10.1097/mpa.0000000000000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
202 Moik F, Prager G, Thaler J, Posch F, Wiedemann S, Schramm T, Englisch C, Mackman N, Pabinger I, Ay C. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. Arterioscler Thromb Vasc Biol 2021;41:2837-47. [PMID: 34470475 DOI: 10.1161/ATVBAHA.121.316463] [Reference Citation Analysis]
203 Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 2018;9:996-1004. [PMID: 30603118 DOI: 10.21037/jgo.2018.05.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
204 Minicozzi P, Cassetti T, Vener C, Sant M. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol 2018;55:52-60. [PMID: 29777994 DOI: 10.1016/j.canep.2018.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
205 Macarulla T, Carrato A, Díaz R, García A, Laquente B, Sastre J, Álvarez R, Muñoz A, Hidalgo M. Management and supportive treatment of frail patients with metastatic pancreatic cancer. J Geriatr Oncol 2019;10:398-404. [PMID: 30005980 DOI: 10.1016/j.jgo.2018.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
206 Holub M, Bartáková E, Stráníková A, Koblihová E, Arientová S, Blahutová M, Máca J, Ryska M. Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery. Mediators Inflamm 2019;2019:6985703. [PMID: 31582902 DOI: 10.1155/2019/6985703] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Liberati D, Marzinotto I, Brigatti C, Dugnani E, Pasquale V, Reni M, Balzano G, Falconi M, Piemonti L, Lampasona V. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Cancer Biomark 2018;22:351-7. [PMID: 29660901 DOI: 10.3233/CBM-181218] [Reference Citation Analysis]
208 Holub K, Conill C. Unveiling the mechanisms of immune evasion in pancreatic cancer: may it be a systemic inflammation responsible for dismal survival? Clin Transl Oncol 2020;22:81-90. [DOI: 10.1007/s12094-019-02113-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
209 Gress TM, Lausser L, Schirra LR, Ortmüller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M. Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material. Oncotarget 2017;8:108223-37. [PMID: 29296236 DOI: 10.18632/oncotarget.22601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
210 Zijlstra M, van der Geest LGM, van Laarhoven HWM, Lemmens VEPP, van de Poll-Franse LV, Raijmakers NJH. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta Oncol 2018;57:1185-91. [PMID: 29741436 DOI: 10.1080/0284186X.2018.1470330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
211 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
212 Li HJ, Chen YT, Yuan SQ. Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study. Medicine (Baltimore) 2018;97:e12094. [PMID: 30142869 DOI: 10.1097/MD.0000000000012094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
213 Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther 2017;10:591-6. [PMID: 28203092 DOI: 10.2147/OTT.S124097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
214 de Liguori Carino N, O'Reilly DA, Siriwardena AK, Valle JW, Radhakrishna G, Pihlak R, McNamara MG. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? Eur J Surg Oncol. 2018;44:1486-1493. [PMID: 30146253 DOI: 10.1016/j.ejso.2018.07.047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
215 Zhou CY, Dong YP, Sun X, Sui X, Zhu H, Zhao YQ, Zhang YY, Mason C, Zhu Q, Han SX. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer Med 2018;7:5525-33. [PMID: 30358133 DOI: 10.1002/cam4.1833] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
216 Bjerring OS, Fristrup CW, Pfeiffer P, Lundell L, Mortensen MB. Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study). British Journal of Surgery 2019;106:1761-8. [DOI: 10.1002/bjs.11290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
217 Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017;19:667-81. [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
218 Kim DW, Lee SS, Kim SO, Kim JH, Kim HJ, Byun JH, Yoo C, Kim KP, Song KB, Kim SC. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score. Radiology 2020;296:541-51. [PMID: 32662759 DOI: 10.1148/radiol.2020200281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
219 Trilla-fuertes L, Gámez-pozo A, Lumbreras-herrera MI, López-vacas R, Heredia-soto V, Ghanem I, López-camacho E, Zapater-moros A, Miguel M, Peña-burgos EM, Palacios E, De Uribe M, Guerra L, Dittmann A, Mendiola M, Fresno Vara JÁ, Feliu J. Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics. Cancers 2022;14:2414. [DOI: 10.3390/cancers14102414] [Reference Citation Analysis]
220 Luo W, Zheng L, Zhang T. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Int Immunopharmacol 2021;90:107199. [PMID: 33246828 DOI: 10.1016/j.intimp.2020.107199] [Reference Citation Analysis]
221 Ristau P, Oetting-Roß C, Büscher A. Coping in patients with pancreatic cancer: a scoping review and narrative synthesis. BMJ Support Palliat Care 2021:bmjspcare-2021-003266. [PMID: 34880064 DOI: 10.1136/bmjspcare-2021-003266] [Reference Citation Analysis]
222 Arya N, Wyse JM, Jayaraman S, Ball CG, Lam E, Paquin SC, Lightfoot P, Sahai AV. A proposal for the ideal algorithm for the diagnosis, staging, and treatment of pancreas masses suspicious for pancreatic adenocarcinoma: Results of a working group of the Canadian Society for Endoscopic Ultrasound. Endosc Ultrasound 2020;9:154-61. [PMID: 32584310 DOI: 10.4103/eus.eus_28_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Bispo M, Marques S, Rio-Tinto R, Fidalgo P, Devière J. The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine. GE Port J Gastroenterol 2021;28:111-20. [PMID: 33791398 DOI: 10.1159/000509197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Ceci C, Atzori MG, Lacal PM, Graziani G. Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. Int J Mol Sci 2020;21:E1388. [PMID: 32085654 DOI: 10.3390/ijms21041388] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
225 Perik TH, van Genugten EAJ, Aarntzen EHJG, Smit EJ, Huisman HJ, Hermans JJ. Quantitative CT perfusion imaging in patients with pancreatic cancer: a systematic review. Abdom Radiol (NY) 2021. [PMID: 34223961 DOI: 10.1007/s00261-021-03190-w] [Reference Citation Analysis]
226 Dengsø KE, Tjørnhøj-Thomsen T, Dalton SO, Christensen BM, Hillingsø J, Thomsen T. Gut disruption impairs rehabilitation in patients curatively operated for pancreaticoduodenal cancer - a qualitative study. BMC Cancer 2018;18:1017. [PMID: 30348133 DOI: 10.1186/s12885-018-4933-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
227 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
228 Lisotti A, Frazzoni L, Fuccio L, Serrani M, Cominardi A, Bazzoli F, Fusaroli P. Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis.Gastrointest Endosc. 2020;91:1234-1241.e4. [PMID: 32006546 DOI: 10.1016/j.gie.2020.01.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
229 Franck C, Müller C, Rosania R, Croner RS, Pech M, Venerito M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers (Basel) 2020;12:E1955. [PMID: 32708493 DOI: 10.3390/cancers12071955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
230 Thobie A, Mulliri A, Dolet N, Eid Y, Bouvier V, Launoy G, Alves A, Dejardin O. Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: A high-resolution population-based cancer registry study. Surg Oncol 2018;27:759-66. [PMID: 30449504 DOI: 10.1016/j.suronc.2018.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
231 Gao S, Pu N, Yin H, Li J, Chen Q, Yang M, Lou W, Chen Y, Zhou G, Li C, Li G, Yan Z, Liu L, Yu J, Wang X. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Ther Adv Med Oncol. 2020;12:1758835920953728. [PMID: 32973929 DOI: 10.1177/1758835920953728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
232 Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers (Basel) 2019;11:E663. [PMID: 31086093 DOI: 10.3390/cancers11050663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
233 Gassner E, Poskaite P. Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. Eur Surg 2019;51:146-52. [DOI: 10.1007/s10353-019-0598-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
234 Doello K, Mesas C, Quiñonero F, Perazzoli G, Cabeza L, Prados J, Melguizo C, Ortiz R. The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study. Cancers (Basel) 2021;13:3169. [PMID: 34201986 DOI: 10.3390/cancers13133169] [Reference Citation Analysis]
235 Kubo H, Ohgi K, Sugiura T, Ashida R, Yamada M, Otsuka S, Yamazaki K, Todaka A, Sasaki K, Uesaka K. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11628-8] [Reference Citation Analysis]
236 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
237 Lin H, Hu P, Zhang H, Deng Y, Yang Z, Zhang L. GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis. Mol Cells 2022;45:329-42. [PMID: 35534193 DOI: 10.14348/molcells.2022.2176] [Reference Citation Analysis]
238 Xiang M, Heestand GM, Chang DT, Pollom EL. Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database. Radiother Oncol 2020;143:101-7. [PMID: 32044168 DOI: 10.1016/j.radonc.2020.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
239 Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdom Radiol (NY) 2021;46:5609-17. [PMID: 34557934 DOI: 10.1007/s00261-021-03284-5] [Reference Citation Analysis]
240 Mattevi C, Garnier J, Marchese U, Ewald J, Gilabert M, Poizat F, Piana G, Delpero JR, Turrini O. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? BMC Surg 2020;20:176. [PMID: 32758203 DOI: 10.1186/s12893-020-00835-3] [Reference Citation Analysis]
241 Paškevičiūtė M, Petrikaitė V. Differences of statin activity in 2D and 3D pancreatic cancer cell cultures. Drug Des Devel Ther 2017;11:3273-80. [PMID: 29180851 DOI: 10.2147/DDDT.S149411] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
242 Landau E, Kalnicki S. The Evolving Role of Radiation in Pancreatic Cancer. Surg Clin North Am 2018;98:113-25. [PMID: 29191268 DOI: 10.1016/j.suc.2017.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
243 Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. JCI Insight 2021;6:141532. [PMID: 33764904 DOI: 10.1172/jci.insight.141532] [Reference Citation Analysis]
244 Shrikhande SV, Barreto S, Sirohi B, Bal M, Shrimali RK, Chacko RT, Chaudhari V, Bhatia V, Kulkarni S, Kaur T, Dhaliwal RS, Rath GK. Indian council of medical research consensus document for the management of pancreatic cancer. Indian Journal of Medical and Paediatric Oncology 2021;40:9-14. [DOI: 10.4103/ijmpo.ijmpo_29_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Pant S, Hubbard J, Martinelli E, Bekaii-saab T. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Critical Reviews in Oncology/Hematology 2018;130:78-91. [DOI: 10.1016/j.critrevonc.2018.07.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
246 González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1052. [PMID: 31349663 DOI: 10.3390/cancers11081052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
247 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
248 Furtado FS, Ferrone CR, Lee SI, Vangel M, Rosman DA, Weekes C, Qadan M, Fernandez-Del Castillo C, Ryan DP, Blaszkowsky LS, Hong TS, Clark JW, Striar R, Groshar D, Cañamaque LG, Umutlu L, Catalano OA. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol 2021;23:456-66. [PMID: 33415677 DOI: 10.1007/s11307-020-01569-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Franck C, Hass P, Malfertheiner P, Ricke J, Seidensticker M, Venerito M. Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion 2018;98:69-74. [DOI: 10.1159/000487359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
250 Huang L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Zadnik V, Primic-Žakelj M, Mägi M, Grützmann R, Besselink MG, Schrotz-King P, Brenner H, Jansen L. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. BMC Med 2019;17:66. [PMID: 30905320 DOI: 10.1186/s12916-019-1304-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
251 Panaro F, Kellil T, Vendrell J, Sega V, Souche R, Piardi T, Leon P, Cassinotto C, Assenat E, Rosso E, Navarro F. Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma. J Surg Oncol 2019;120:483-93. [PMID: 31197842 DOI: 10.1002/jso.25580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
252 Carrato A, Vieitez JM, Benavides M, Rodriguez-Garrote M, Castillo A, Ogalla GD, Bermejo LG, Ruiz de Mena I, Guillén-Ponce C, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Eur J Cancer 2020;139:51-8. [PMID: 32977220 DOI: 10.1016/j.ejca.2020.07.035] [Reference Citation Analysis]
253 Daamen LA, Groot VP, Heerkens HD, Intven MP, van Santvoort HC, Molenaar IQ. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB 2018;20:297-304. [DOI: 10.1016/j.hpb.2017.11.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
254 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
255 Riviere DM, van Geenen EJM, van der Kolk BM, Nagtegaal ID, Radema SA, van Laarhoven CJHM, Hermans JJ. Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. Abdom Radiol (NY) 2019;44:1756-65. [PMID: 30659309 DOI: 10.1007/s00261-018-1867-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
256 Makler A, Asghar W. Exosomal biomarkers for cancer diagnosis and patient monitoring. Expert Rev Mol Diagn 2020;20:387-400. [PMID: 32067543 DOI: 10.1080/14737159.2020.1731308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
257 Osther K, Förnvik K, Liljedahl E, Salford LG, Redebrandt HN. Upregulation of C1-inhibitor in pancreatic cancer. Oncotarget 2019;10:5703-12. [PMID: 31620245 DOI: 10.18632/oncotarget.27191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
258 Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1758835920940887. [PMID: 32782488 DOI: 10.1177/1758835920940887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
259 Kim Y, Baek W. Caring experiences of family caregivers of patients with pancreatic cancer: an integrative literature review. Support Care Cancer 2022. [PMID: 34993653 DOI: 10.1007/s00520-021-06793-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Chan DL, Cheung M, Earle CC, Coburn N, Mittmann N, Rahman F, Liu N, Singh S. Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. J Gastrointest Cancer 2020;51:189-95. [PMID: 30972631 DOI: 10.1007/s12029-019-00235-8] [Reference Citation Analysis]
261 Moris D, Machairas N, Tsilimigras DI, Prodromidou A, Ejaz A, Weiss M, Hasemaki N, Felekouras E, Pawlik TM. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2019;26:1657-1668. [PMID: 30843163 DOI: 10.1245/s10434-019-07261-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
262 Werthmann PG, Inter P, Welsch T, Sturm AK, Grützmann R, Debus M, Sterner MG, Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report.Medicine (Baltimore). 2018;97:e13243. [PMID: 30544385 DOI: 10.1097/MD.0000000000013243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Chen J, Hua Q, Wang H, Zhang D, Zhao L, Yu D, Pi G, Zhang T, Lin Z. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer 2021;21:853. [PMID: 34301232 DOI: 10.1186/s12885-021-08605-x] [Reference Citation Analysis]
264 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
265 de Oliveira G, Freire PP, Cury SS, de Moraes D, Oliveira JS, Dal-Pai-Silva M, Reis PP, Carvalho RF. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020;12:716. [PMID: 32197468 DOI: 10.3390/cancers12030716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
266 Kapp M, Kosmala A, Kircher S, Luber V, Kunzmann V. Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater. Case Rep Oncol. 2016;9:15-24. [PMID: 26933414 DOI: 10.1159/000443304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
267 Recio-Boiles A, Vondrak J, Veeravelli S, Mancuso JJ, Saboda K, Roe DJ, Riaz IB, Scott AJ, Elquza E, McBride A, Babiker HM. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. Ann Pancreat Cancer 2020;3:2. [PMID: 32313882 DOI: 10.21037/apc.2020.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Li M, Song SW, Ge Y, Jin JY, Li XY, Tan XD. The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells. Ann Transl Med 2020;8:1234. [PMID: 33178766 DOI: 10.21037/atm-20-5880] [Reference Citation Analysis]
269 Wu H, Guo JC, Yang SH, Tien YW, Kuo SH. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. J Clin Med 2019;8:E1115. [PMID: 31357636 DOI: 10.3390/jcm8081115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
270 Rigiroli F, Hoye J, Lerebours R, Lafata KJ, Li C, Meyer M, Lyu P, Ding Y, Schwartz FR, Mettu NB, Zani S Jr, Luo S, Morgan DE, Samei E, Marin D. CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Radiology 2021;301:610-22. [PMID: 34491129 DOI: 10.1148/radiol.2021210699] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Tekin C, Aberson HL, Bijlsma MF, Spek CA. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion. BMC Cancer 2020;20:1183. [PMID: 33267818 DOI: 10.1186/s12885-020-07697-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
272 Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, Wahiba B, Louafi S, Gratet A, Miglianico L, Laharie H, Bouhier Leporrier K, Thirot Bidault A, Texereau P, Coriat R, Terrebonne E, Gouttebel MC, Malka D, Bachet JB, Lepage C, Taieb J; PRODIGE 37 Investigators/Collaborators. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). Eur J Cancer 2020;136:25-34. [PMID: 32623182 DOI: 10.1016/j.ejca.2020.05.018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
273 Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R, Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG, Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L, Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP, Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G, Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU, Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V, Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ, Schaaf M, Hausen GZ, Götze TO; Arbeitsgemeinschaft Internistische Onkologie (AIO). Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. Int J Cancer 2021;148:1478-88. [PMID: 33038277 DOI: 10.1002/ijc.33336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
274 Mouradides C, Taha A, Borbath I, Deprez PH, Moreels TG. How to treat intestinal obstruction due to malignant recurrence after Whipple’s resection for pancreatic head cancer: Description of 2 new endoscopic techniques. World J Gastroenterol 2017; 23(33): 6181-6186 [PMID: 28970734 DOI: 10.3748/wjg.v23.i33.6181] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
275 Capistrano I R, Vangestel C, Vanpachtenbeke H, Fransen E, Staelens S, Apers S, Pieters L. Coadministration of a Gloriosa superba extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model. Phytomedicine 2016;23:1434-40. [PMID: 27765363 DOI: 10.1016/j.phymed.2016.07.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
276 Kümler I, Eefsen RL, Sørensen PG, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemother Pharmacol 2019;84:441-6. [PMID: 30949758 DOI: 10.1007/s00280-019-03819-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
277 van Veldhuisen E, van den Oord C, Brada LJ, Walma MS, Vogel JA, Wilmink JW, Del Chiaro M, van Lienden KP, Meijerink MR, van Tienhoven G, Hackert T, Wolfgang CL, van Santvoort H, Groot Koerkamp B, Busch OR, Molenaar IQ, van Eijck CH, Besselink MG; Dutch Pancreatic Cancer Group and International Collaborative Group on Locally Advanced Pancreatic Cancer. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers (Basel) 2019;11:E976. [PMID: 31336859 DOI: 10.3390/cancers11070976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
278 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
279 Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Reference Citation Analysis]
280 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11. [PMID: 30965637 DOI: 10.3390/cancers11040497] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
281 Palmieri LJ, Coriat R. 18F-FDG PET/CT in pancreatic adenocarcinoma: On the edge of a paradigm shift? Diagn Interv Imaging 2019;100:731-3. [PMID: 31780041 DOI: 10.1016/j.diii.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
282 Strijker M, van Veldhuisen E, van der Geest LG, Busch OR, Bijlsma MF, Haj Mohammad N, Homs MY, van Hooft JE, Verheij J, de Vos-Geelen J, Wilmink JW, Steyerberg WEW, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Biomarkers 2021;26:325-34. [PMID: 33663300 DOI: 10.1080/1354750X.2021.1893814] [Reference Citation Analysis]
283 Breen WG, Jethwa KR, Yu NY, Spears GM, Harmsen WS, Miller RC, Ashman JB, Rule WG, Sio TT, Neben-Wittich MA, Haddock MG, Mahipal A, Truty MJ, Hallemeier CL, Merrell KW. Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. Pract Radiat Oncol 2021;11:e63-9. [PMID: 32712461 DOI: 10.1016/j.prro.2020.06.011] [Reference Citation Analysis]
284 Zundler S, Strobel D, Manger B, Neurath MF, Wildner D. Pancreatic Panniculitis and Polyarthritis. Curr Rheumatol Rep 2017;19. [DOI: 10.1007/s11926-017-0690-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
285 Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, De Vita F, Falconi M, Frassineti GL, Giommoni E, Macchini M, Malleo G, Silvestris N, Tudisco A, Vasile E, Reni M. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Crit Rev Oncol Hematol 2021;169:103571. [PMID: 34923121 DOI: 10.1016/j.critrevonc.2021.103571] [Reference Citation Analysis]
286 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
287 Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderón VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhreidze J, Ponce S, Bunn PA. RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer 2022. [PMID: 35195913 DOI: 10.1002/cncr.34123] [Reference Citation Analysis]
288 Giannone F, Capretti G, Abu Hilal M, Boggi U, Campra D, Cappelli C, Casadei R, De Luca R, Falconi M, Giannotti G, Gianotti L, Girelli R, Gollini P, Ippolito D, Limerutti G, Maganuco L, Malagnino V, Malleo G, Morone M, Mosconi C, Mrakic F, Palumbo D, Salvia R, Sgroi S, Zerbi A, Balzano G. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectability Status Criteria. Annals of Surgery Open 2021;2:e087. [DOI: 10.1097/as9.0000000000000087] [Reference Citation Analysis]
289 de Jong EJM, Mommers I, Fariña Sarasqueta A, van der Geest LG, Heij L, de Hingh IHJT, Homs MYV, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Geurts SME, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncol 2022;:1-6. [PMID: 35382678 DOI: 10.1080/0284186X.2022.2053199] [Reference Citation Analysis]
290 Gränsmark E, Bågenholm Bylin N, Blomstrand H, Fredrikson M, Åvall-Lundqvist E, Elander NO. Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. Front Oncol 2020;10:1176. [PMID: 32850339 DOI: 10.3389/fonc.2020.01176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
291 Tseimakh AE, Lazarev AF, Sekerzhinskaya EL, Kurtukov VA, Mitshenko AN, Teplukhin VN, Shoykhet YN. Palliative treatment with the use of photodynamic therapy of patients with malignant tumors of pancreatobiliary zone complicated by obstructive jaundice. Biomedical photonics 2020;9:4-12. [DOI: 10.24931/2413-9432-2020-9-1-4-12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130 [PMID: 28028360 DOI: 10.3748/wjg.v22.i46.10124] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
293 Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open 2021;7:100356. [PMID: 34953400 DOI: 10.1016/j.esmoop.2021.100356] [Reference Citation Analysis]
294 Wei G, Luo Q, Fang J, Li X, Shi Y, Li Y, Sun L. The Sex Features of Patients With Solid Pseudopapillary Neoplasms of the Pancreas: A Retrospective Study. Front Oncol 2022;12:844182. [DOI: 10.3389/fonc.2022.844182] [Reference Citation Analysis]
295 Zhou HF, Han YQ, Lu J, Wei JW, Guo JH, Zhu HD, Huang M, Ji JS, Lv WF, Chen L, Zhu GY, Jin ZC, Tian J, Teng GJ. Radiomics Facilitates Candidate Selection for Irradiation Stents Among Patients With Unresectable Pancreatic Cancer. Front Oncol 2019;9:973. [PMID: 31612111 DOI: 10.3389/fonc.2019.00973] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
296 Giommoni E, Maiello E, Vaccaro V, Rondini E, Vivaldi C, Tortora G, Toppo L, Giordano G, Latiano TP, Lamperini C, Pillozzi S, Boni L, Antonuzzo L, Di Costanzo F. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Curr Oncol 2021;28:1761-72. [PMID: 34066784 DOI: 10.3390/curroncol28030164] [Reference Citation Analysis]
297 Hand F, Conlon KC. Pancreatic cancer. Surgery (Oxford) 2019;37:319-26. [DOI: 10.1016/j.mpsur.2019.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
298 Bulle A, Dekervel J, Deschuttere L, Nittner D, Van Cutsem E, Verslype C, van Pelt J. Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts. Onco Targets Ther 2020;13:6907-16. [PMID: 32764982 DOI: 10.2147/OTT.S245134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Bor R, Vasas B, Fábián A, Bálint A, Farkas K, Milassin Á, Czakó L, Rutka M, Molnár T, Szűcs M, Tiszlavicz L, Kaizer L, Hamar S, Szepes Z. Prospective comparison of slow-pull and standard suction techniques of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of solid pancreatic cancer. BMC Gastroenterol 2019;19:6. [PMID: 30626331 DOI: 10.1186/s12876-018-0921-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
300 Rautakorpi L, Jyrkkiö S, Löyttyniemi E, Hirvonen O. End-of-life care among patients with pancreatic cancer with or without palliative intervention: a retrospective single-centre study. Acta Oncol 2021;60:106-11. [PMID: 32812832 DOI: 10.1080/0284186X.2020.1806356] [Reference Citation Analysis]
301 Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016;2016:9795269. [PMID: 28042579 DOI: 10.1155/2016/9795269] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
302 He C, Wang J, Zhang Y, Cai Z, Lin X, Li S. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. Cancer Med. 2020;9:4699-4710. [PMID: 32410380 DOI: 10.1002/cam4.3119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
303 Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol 2019;36:83. [PMID: 31444639 DOI: 10.1007/s12032-019-1306-9] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
304 Gallmeier E, Gress TM. [Pancreatic ductal adenocarcinoma]. Internist (Berl). 2018;59:805-822. [PMID: 29980819 DOI: 10.1007/s00108-018-0460-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Lin JY, Zhang XM, Kou JT, Fa H, Zhang XX, Dai Y, He Q. Analysis of prognostic factors for pancreatic head cancer according to para-aortic lymph node. Cancer Med. 2016;5:2701-2707. [PMID: 27541833 DOI: 10.1002/cam4.853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
306 George B, Kent M, Surinach A, Lamarre N, Cockrum P. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:754687. [PMID: 34671563 DOI: 10.3389/fonc.2021.754687] [Reference Citation Analysis]
307 Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D;  BACAP Consortium. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology 2020; 158: 1346-1358. e4. [PMID: 31843588 DOI: 10.1053/j.gastro.2019.12.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
308 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
309 Drewes R, Omari J, Manig M, Seidensticker M, Hass P, Ricke J, Powerski M, Pech M. Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. J Contemp Brachytherapy 2019;11:329-36. [PMID: 31523233 DOI: 10.5114/jcb.2019.87269] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Zarkavelis G, Kotoula V, Kolliou GA, Papadopoulou K, Tikas I, Karavasilis V, Samantas E, Dervenis C, Efstratiou I, Nicolaou I, Apessou D, Kafiri G, Koletsa T, Bompolaki I, Rallis G, Batistatou A, Glantzounis G, Pectasides D, Fountzilas G, Pentheroudakis G. Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). ESMO Open 2019;4:e000525. [PMID: 31673425 DOI: 10.1136/esmoopen-2019-000525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
311 Nebot-Villacampa MJ, Zafra-Morales R, Alfaro-Olea A, Marín-Gorricho R, Casajús-Navasal A, Uriarte-Pinto M. Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma. J Oncol Pharm Pract 2020;26:603-11. [PMID: 31315550 DOI: 10.1177/1078155219862035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
312 Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med 2016;10:1197-207. [PMID: 27673558 DOI: 10.2217/bmm-2016-0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
313 Roviello G, Ramello M, Catalano M, D'Angelo A, Conca R, Gasperoni S, Dreoni L, Petrioli R, Ianza A, Nobili S, Aieta M, Mini E. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Sci Rep 2020;10:19281. [PMID: 33159172 DOI: 10.1038/s41598-020-76465-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, Pracht M, Le Sourd S, Edeline J, Lièvre A. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease 2017;49:692-6. [DOI: 10.1016/j.dld.2017.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
315 Ohki K, Igarashi T, Ashida H, Shiraishi M, Nozawa Y, Ojiri H. Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging. Pol J Radiol 2019;84:e153-61. [PMID: 31019610 DOI: 10.5114/pjr.2019.84193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
316 Flebbe H, Spitzner M, Marquet PE, Gaedcke J, Ghadimi BM, Rieken S, Schneider G, Koenig AO, Grade M. Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy. Cancers 2022;14:1301. [DOI: 10.3390/cancers14051301] [Reference Citation Analysis]
317 Wang X, Hu L, Yang X, Chen F, Xu H, Yu H, Song Z, Fei J, Zhong Z. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Exp Ther Med 2021;22:1140. [PMID: 34504586 DOI: 10.3892/etm.2021.10574] [Reference Citation Analysis]
318 Cassinotto C, Dohan A, Zogopoulos G, Chiche L, Laurent C, Sa-Cunha A, Cuggia A, Reinhold C, Gallix B. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Eur J Radiol 2017;95:33-8. [PMID: 28987689 DOI: 10.1016/j.ejrad.2017.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
319 Mattila N, Seppänen H, Mustonen H, Przybyla B, Haglund C, Lassila R. Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clin Appl Thromb Hemost 2018;24:1267-75. [PMID: 29865859 DOI: 10.1177/1076029618779133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
320 Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers (Basel) 2021;13:4259. [PMID: 34503069 DOI: 10.3390/cancers13174259] [Reference Citation Analysis]
321 Castillo Tuñón JM, Valle Rodas ME, Botello Martínez F, Rojas Holguín A, López Guerra D, Santos Naharro J, Jaén Torrejímeno I, Blanco Fernández G. Implementation of a regional reference center in pancreatic surgery. Experience after 631 procedures. Cir Esp (Engl Ed) 2021;99:745-56. [PMID: 34794902 DOI: 10.1016/j.cireng.2021.11.001] [Reference Citation Analysis]
322 Li SS, Zhou CY, Liao R, Xiong L, Weng NN, Zhao YQ, Mason C, Gou HF, Yi C, Zhu Q. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2020;99:e19413. [PMID: 32243360 DOI: 10.1097/MD.0000000000019413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
323 Schönrogge M, Kerndl H, Zhang X, Kumstel S, Vollmar B, Zechner D. α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Cell Signal 2018;47:101-8. [PMID: 29609037 DOI: 10.1016/j.cellsig.2018.03.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
324 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
325 Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Eur J Cancer 2019;106:24-33. [PMID: 30458340 DOI: 10.1016/j.ejca.2018.09.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
326 Tekin C, Scicluna BP, Lodestijn SC, Shi K, Bijlsma MF, Spek CA. Protease-activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma. Mol Oncol 2021. [PMID: 33932087 DOI: 10.1002/1878-0261.12971] [Reference Citation Analysis]
327 de Jong EJM, Janssen QP, Simons TFA, Besselink MG, Bonsing BA, Bouwense SAW, Geurts SME, Homs MYV, de Meijer VE, Tjan-Heijnen VCG, van Laarhoven HWM, Valkenburg-van Iersel LBJ, Wilmink JW, van der Geest LG, Koerkamp BG, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Int J Cancer 2021. [PMID: 34935139 DOI: 10.1002/ijc.33916] [Reference Citation Analysis]
328 Achalandabaso Boira M, Di Martino M, Gordillo C, Adrados M, Martín-Pérez E. GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival. BMC Cancer 2020;20:909. [PMID: 32967636 DOI: 10.1186/s12885-020-07409-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78-87. [PMID: 30654298 DOI: 10.1016/j.ejca.2018.12.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 20.0] [Reference Citation Analysis]
330 Jalal M, Campbell JA, Wadsley J, Hopper AD. Computed Tomographic Sarcopenia in Pancreatic Cancer: Further Utilization to Plan Patient Management. J Gastrointest Cancer 2021;52:1183-7. [PMID: 34292498 DOI: 10.1007/s12029-021-00672-4] [Reference Citation Analysis]
331 Martínez de Juan F, Reolid Escribano M, Martínez Lapiedra C, Maia de Alcantara F, Caballero Soto M, Calatrava Fons A, Machado I. Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a CDKN2A germline mutation carrier. World J Gastrointest Oncol 2017; 9(9): 390-396 [PMID: 28979722 DOI: 10.4251/wjgo.v9.i9.390] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
332 Tavares Barroso M, Costa B, Rebelo de Almeida C, Castillo Martin M, Couto N, Carvalho T, Fior R. Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening. Cells 2021;10:2077. [PMID: 34440847 DOI: 10.3390/cells10082077] [Reference Citation Analysis]
333 Lee MKC, Grimmond SM, McArthur GA, Sheppard KE. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:5136. [PMID: 34680285 DOI: 10.3390/cancers13205136] [Reference Citation Analysis]
334 Li YQ, Pan SB, Yan SS, Jin ZD, Huang HJ, Sun LQ. Impact of parenchyma-preserving surgical methods on treating patients with solid pseudopapillary neoplasms: A retrospective study with a large sample size. World J Gastrointest Surg 2022; 14(2): 174-184 [DOI: 10.4240/wjgs.v14.i2.174] [Reference Citation Analysis]
335 Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel) 2021;11:2166. [PMID: 34829513 DOI: 10.3390/diagnostics11112166] [Reference Citation Analysis]
336 Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol 2020;11:55-60. [PMID: 32175105 DOI: 10.21037/jgo.2019.10.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Rotolo S, Ferracci F, Santullo F, Lodoli C, Inzani F, Abatini C, Pacelli F, Di Giorgio A. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin. Int J Surg Case Rep 2020;77S:S75-8. [PMID: 33191190 DOI: 10.1016/j.ijscr.2020.10.054] [Reference Citation Analysis]
338 Henriksen A, Dyhl-polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treatment Reviews 2019;78:17-30. [DOI: 10.1016/j.ctrv.2019.06.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
339 Larentzakis A, Anagnostou E, Georgiou K, Vrakopoulou GZ, Zografos CG, Zografos GC, Toutouzas KG. Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review. Oncol Lett 2021;21:246. [PMID: 33664810 DOI: 10.3892/ol.2021.12507] [Reference Citation Analysis]
340 van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, van Hooft JE, Besselink MG. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol. 2019;16:676-689. [PMID: 31527862 DOI: 10.1038/s41575-019-0195-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 13.7] [Reference Citation Analysis]
341 Hodolic M, Ambrosini V, Fanti S. Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer. Nucl Med Commun 2020;41:411-5. [PMID: 32168264 DOI: 10.1097/MNM.0000000000001172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
342 Hogendorf P, Skulimowski A, Durczyński A, Kumor A, Poznańska G, Oleśna A, Rut J, Strzelczyk J. A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion. Dis Markers 2017;2017:8629712. [PMID: 28356610 DOI: 10.1155/2017/8629712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
343 Kapszewicz M, Małecka-Wojciesko E. Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers-Is There Anything in Sight? J Clin Med 2021;10:5463. [PMID: 34830745 DOI: 10.3390/jcm10225463] [Reference Citation Analysis]
344 Erdem S, Bolli M, Müller SA, von Flüe M, White R, Worni M. Role of lymphadenectomy in resectable pancreatic cancer. Langenbecks Arch Surg 2020;405:889-902. [PMID: 32902706 DOI: 10.1007/s00423-020-01980-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Castel-kremer E, De Talhouet S, Charlois A, Graillot E, Chopin-laly X, Adham M, Comte B, Lombard-bohas C, Walter T, Boschetti G. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Journal of Geriatric Oncology 2018;9:373-81. [DOI: 10.1016/j.jgo.2018.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
346 Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, Melisi D. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1131. [PMID: 32366019 DOI: 10.3390/cancers12051131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
347 Loosen SH, Luedde M, Lurje G, Spehlmann M, Paffenholz P, Ulmer TF, Tacke F, Vucur M, Trautwein C, Neumann UP, Luedde T, Roderburg C. Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. Dis Markers. 2019;2019:5603474. [PMID: 31772690 DOI: 10.1155/2019/5603474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
348 Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 [PMID: 30487953 DOI: 10.4251/wjgo.v10.i11.421] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
349 Eriksen RØ, Strauch LS, Sandgaard M, Kristensen TS, Nielsen MB, Lauridsen CA. Dynamic Contrast-Enhanced CT in Patients with Pancreatic Cancer. Diagnostics (Basel) 2016;6:E34. [PMID: 27608045 DOI: 10.3390/diagnostics6030034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
350 Sahai V, Saif MW, Kalyan A, Philip PA, Rocha-Lima CM, Ocean A, Ondovik MS, Simeone DM, Banerjee S, Bhore R, Louis CU, Picozzi V. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. J Pancreat Cancer 2019;5:35-42. [PMID: 31559379 DOI: 10.1089/pancan.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
351 Guillén-ponce C, Blázquez J, González I, de-Madaria E, Montáns J, Carrato A. Diagnosis and staging of pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1205-16. [DOI: 10.1007/s12094-017-1681-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
352 Huang L, Jansen L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Primic-žakelj M, Zadnik V, Mägi M, Pulte D, Schrotz-king P, Brenner H. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study: Nonsurgical therapies for PaC in Europe and USA. Int J Cancer 2018;143:3227-39. [DOI: 10.1002/ijc.31628] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
353 Skulimowski A, Durczyński A, Strzelczyk J, Hogendorf P. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature. Biomarkers 2021;26:287-95. [PMID: 33459070 DOI: 10.1080/1354750X.2021.1876770] [Reference Citation Analysis]
354 Pokataev I, Kudaibergenova A, Artemyeva A, Popova A, Rumyantsev A, Podluzhny D, Kudashkin N, Fedyanin M, Tryakin A, Tjulandin S. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer. J Gastrointest Canc 2019;50:478-84. [DOI: 10.1007/s12029-018-0103-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Weinrich M, Bochow J, Kutsch AL, Alsfasser G, Weiss C, Klar E, Rau BM. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Ann Med Surg (Lond) 2018;32:32-7. [PMID: 30034801 DOI: 10.1016/j.amsu.2018.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
356 Feng Z, Qian H, Li K, Lou J, Wu Y, Peng C. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:676291. [PMID: 34095229 DOI: 10.3389/fmolb.2021.676291] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 Yoshida T, Yamashita Y, Kitano M. Endoscopic Ultrasound for Early Diagnosis of Pancreatic Cancer. Diagnostics (Basel) 2019;9:E81. [PMID: 31344904 DOI: 10.3390/diagnostics9030081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
358 Alizadeh Savareh B, Asadzadeh Aghdaie H, Behmanesh A, Bashiri A, Sadeghi A, Zali M, Shams R. A machine learning approach identified a diagnostic model for pancreatic cancer through using circulating microRNA signatures. Pancreatology. 2020;20:1195-1204. [PMID: 32800647 DOI: 10.1016/j.pan.2020.07.399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
359 Ehrlich D, Ather N, Rahal H, Donahue TR, Hines OJ, Kim S, Sedarat A, Muthusamy VR, Watson R. The Utility of EUS-FNA to Determine Surgical Candidacy in Patients with Pancreatic Cancer after Neoadjuvant Therapy. J Gastrointest Surg 2020;24:2807-13. [DOI: 10.1007/s11605-019-04415-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
360 Galanopoulos M, Doukatas A, Gkeros F, Viazis N, Liatsos C. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy. World J Gastroenterol 2021; 27(24): 3568-3580 [PMID: 34239270 DOI: 10.3748/wjg.v27.i24.3568] [Reference Citation Analysis]
361 Masuda H, Kotecha K, Maitra R, Gill AJ, Mittal A, Samra JS. Clinical suspicion of pancreatic cancer despite negative endoscopic ultrasound-guided fine-needle aspiration biopsy. ANZ J Surg 2021. [PMID: 34636123 DOI: 10.1111/ans.17256] [Reference Citation Analysis]
362 Thobie A, Mulliri A, Bouvier V, Launoy G, Alves A, Dejardin O. Same Chance of Accessing Resection? Impact of Socioeconomic Status on Resection Rates Among Patients with Pancreatic Adenocarcinoma-A Systematic Review. Health Equity 2021;5:143-50. [PMID: 33778318 DOI: 10.1089/heq.2019.0099] [Reference Citation Analysis]
363 Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol 2019;30:1959-68. [PMID: 31562758 DOI: 10.1093/annonc/mdz406] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
364 Romano R, Picca A, Eusebi LHU, Marzetti E, Calvani R, Moro L, Bucci C, Guerra F. Extracellular Vesicles and Pancreatic Cancer: Insights on the Roles of miRNA, lncRNA, and Protein Cargos in Cancer Progression. Cells 2021;10:1361. [PMID: 34205944 DOI: 10.3390/cells10061361] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
365 Rhee H, Park MS. The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. Korean J Radiol 2021;22:23-40. [PMID: 32901458 DOI: 10.3348/kjr.2019.0862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
366 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1-10. [PMID: 29564165 DOI: 10.21037/jgo.2017.10.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
367 Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Cancers (Basel) 2019;11:E1068. [PMID: 31357748 DOI: 10.3390/cancers11081068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
368 Niesen W, Primavesi F, Gasteiger S, Neoptolemos J, Hackert T, Stättner S. Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. Eur Surg 2019;51:153-64. [DOI: 10.1007/s10353-019-0589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
369 Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol 2021;26:941-50. [PMID: 33483857 DOI: 10.1007/s10147-021-01859-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
370 Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J, Ceyhan GO, Schorn S;  RESPECT-study group. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020;20:1131-1138. [PMID: 32739267 DOI: 10.1016/j.pan.2020.06.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
371 Sasaki M, Nakamura M, Mukumoto N, Goto Y, Ishihara Y, Nakata M, Sugimoto N, Mizowaki T. Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases. J Appl Clin Med Phys 2019;20:118-26. [PMID: 31539194 DOI: 10.1002/acm2.12720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
372 Wei M, Gu B, Song S, Zhang B, Wang W, Xu J, Yu X, Shi S. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Front Oncol 2021;11:650266. [PMID: 34055620 DOI: 10.3389/fonc.2021.650266] [Reference Citation Analysis]
373 Jooste V, Bengrine-lefevre L, Manfredi S, Quipourt V, Grosclaude P, Facy O, Lepage C, Ghiringhelli F, Bouvier A. Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Cancers 2022;14:1675. [DOI: 10.3390/cancers14071675] [Reference Citation Analysis]
374 Hansen SEJ, Langsted A, Varbo A, Madsen CM, Tybjærg-Hansen A, Nordestgaard BG. Low and high pancreatic amylase is associated with pancreatic cancer and chronic pancreatitis. Eur J Epidemiol 2021;36:975-84. [PMID: 34482515 DOI: 10.1007/s10654-021-00801-0] [Reference Citation Analysis]
375 Zhang X, Wu Q, Fan H, He Q, Lang R. Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a feasible method to avoid left-sided portal hypertension. Cancer Med 2021;10:5448-55. [PMID: 34190423 DOI: 10.1002/cam4.4093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
376 Carrato A, Melisi D, Prager G, Westphalen CB, Ferreras A, D'Esquermes N, Taieb J, Mercadé TM. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Future Oncol 2021;17:1843-54. [PMID: 33663227 DOI: 10.2217/fon-2020-0749] [Reference Citation Analysis]
377 Salazar J, Pérez-Bracchiglione J, Salas-Gama K, Antequera A, Auladell-Rispau A, Dorantes-Romandía R, Meade AG, Jesús Quintana M, Requeijo C, Rodríguez-Grijalva G, Santero M, Acosta-Dighero R, Solà I, Urrútia G, Bonfill Cosp X; Systemic Treatments for Advanced Digestive Cancer Research. Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews. Eur J Cancer 2021;154:82-91. [PMID: 34252759 DOI: 10.1016/j.ejca.2021.05.034] [Reference Citation Analysis]
378 Wang ZJ, Arif-tiwari H, Zaheer A, Ameli S, Bhosale PR, Do RK, Goenka AH, Guimares AR, Sangster GP, Soloff EV, Tamm EP, Zins M, Kambadakone AR. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol 2020;45:4273-89. [DOI: 10.1007/s00261-020-02723-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
379 Le Grazie M, Conti Bellocchi MC, Bernardoni L, Fusaroli P, Manfrin E, Pallio S, Gabbrielli A, Crinò SF. Diagnostic yield of endoscopic ultrasound-guided tissue acquisition of solid pancreatic lesions after inconclusive percutaneous ultrasound-guided tissue acquisition. Scand J Gastroenterol 2020;55:1108-13. [PMID: 32684051 DOI: 10.1080/00365521.2020.1794021] [Reference Citation Analysis]
380 The RICOCHET Study Group, West Midlands Research Collaborative. Receipt of Curative Resection or Palliative Care for Hepatopancreaticobiliary Tumours (RICOCHET): Protocol for a Nationwide Collaborative Observational Study. JMIR Res Protoc 2019;8:e13566. [DOI: 10.2196/13566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
381 Kirkegård J, Aahlin EK, Al-Saiddi M, Bratlie SO, Coolsen M, de Haas RJ, den Dulk M, Fristrup C, Harrison EM, Mortensen MB, Nijkamp MW, Persson J, Søreide JA, Wigmore SJ, Wik T, Mortensen FV. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Br J Surg 2019;106:756-64. [PMID: 30830974 DOI: 10.1002/bjs.11093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
382 Lee JW, O JH, Choi M, Choi JY. Impact of F-18 Fluorodeoxyglucose PET/CT and PET/MRI on Initial Staging and Changes in Management of Pancreatic Ductal Adenocarcinoma: A Systemic Review and Meta-Analysis. Diagnostics (Basel). 2020;10. [PMID: 33202682 DOI: 10.3390/diagnostics10110952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
383 Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford) 2018;20:379-84. [PMID: 29336893 DOI: 10.1016/j.hpb.2017.12.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
384 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Reference Citation Analysis]
385 Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep 2019;46:6629-45. [PMID: 31486978 DOI: 10.1007/s11033-019-05058-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
386 Okamoto S, Shiga T, Tamaki N. Clinical Perspectives of Theranostics. Molecules 2021;26:2232. [PMID: 33924345 DOI: 10.3390/molecules26082232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Montejo Gañán I, Ángel Ríos LF, Sarría Octavio de Toledo L, Martínez Mombila ME, Ros Mendoza LH. Staging pancreatic carcinoma by computed tomography. Radiologia (Engl Ed) 2018;60:10-23. [PMID: 29078990 DOI: 10.1016/j.rx.2017.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
388 Vandeputte M, D'Hondt M, Willems E, De Meyere C, Parmentier I, Vansteenkiste F. Stepwise implementation of laparoscopic pancreatic surgery. Case series of a single centre's experience. Int J Surg 2019;72:137-43. [PMID: 31704423 DOI: 10.1016/j.ijsu.2019.10.037] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
389 Chung KH, Ryu JK, Son JH, Lee JW, Jang DK, Lee SH, Kim YT. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Gut Liver. 2017;11:298-305. [PMID: 27965478 DOI: 10.5009/gnl16307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
390 Nigri G, Petrucciani N, Belloni E, Lucarini A, Aurello P, D'Angelo F, di Saverio S, Fancellu A, Ramacciato G. Distal Pancreatectomy with Celiac Axis Resection: Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1967. [PMID: 33921838 DOI: 10.3390/cancers13081967] [Reference Citation Analysis]
391 Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Cancers (Basel) 2021;13:4939. [PMID: 34638422 DOI: 10.3390/cancers13194939] [Reference Citation Analysis]
392 Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs. 2018;36:732-741. [PMID: 29616439 DOI: 10.1007/s10637-018-0598-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 14.5] [Reference Citation Analysis]
393 Pu N, Lv Y, Zhao G, Lee W, Nuerxiati A, Wang D, Xu X, Kuang T, Wu W, Lou W. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Future Oncol 2018;14:165-75. [PMID: 29226705 DOI: 10.2217/fon-2017-0380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
394 van Riet PA, Quispel R, Cahen DL, Snijders-Kruisbergen MC, van Loenen P, Erler NS, Poley JW, van Driel LMJW, Mulder SA, Veldt BJ, Leeuwenburgh I, Anten MGF, Honkoop P, Thijssen AY, Hol L, Hadithi M, Fitzpatrick CE, Schot I, Bergmann JF, Bhalla A, Bruno MJ, Biermann K. Diagnostic yield and agreement on fine-needle specimens from solid pancreatic lesions : comparing the smear technique to liquid-based cytology. Endosc Int Open. 2020;8:E155-E162. [PMID: 32010748 DOI: 10.1055/a-1038-4103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
395 Itoi T, Sugimoto M, Umeda J, Sofuni A, Tsuchiya T, Tsuji S, Tanaka R, Tonozuka R, Honjo M, Moriyasu F, Kasuya K, Nagakawa Y, Abe Y, Takano K, Kawachi S, Shimazu M, Soga T, Tomita M, Sunamura M. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Int J Mol Sci 2017;18:E767. [PMID: 28375170 DOI: 10.3390/ijms18040767] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
396 Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther 2018;35:1564-77. [PMID: 30209750 DOI: 10.1007/s12325-018-0784-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
397 Lewis AR, Valle JW, McNamara MG. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? World J Gastroenterol 2016; 22(32): 7175-7185 [PMID: 27621566 DOI: 10.3748/wjg.v22.i32.7175] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
398 Choi CC, Choi J, Houli N, Smith M, Usatoff V, Lipton L, Chan S. Evaluation of palliative treatments in unresectable pancreatic cancer. ANZ J Surg 2021;91:915-20. [PMID: 33870626 DOI: 10.1111/ans.16669] [Reference Citation Analysis]
399 Doleh Y, Lal LS, Blauer-Petersen C, Antico G, Pishvaian M. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Med 2020;9:3463-76. [PMID: 32212262 DOI: 10.1002/cam4.3011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
400 Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 2017;10:631-45. [PMID: 28835777 DOI: 10.1177/1756283X17713879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
401 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
402 Pflüger MJ, Felsenstein M, Schmocker R, Wood LD, Hruban R, Fujikura K, Rozich N, van Oosten F, Weiss M, Burns W, Yu J, Cameron J, Pratschke J, Wolfgang CL, He J, Burkhart RA. Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature. Surg Open Sci 2020;2:32-40. [PMID: 32954246 DOI: 10.1016/j.sopen.2020.06.003] [Reference Citation Analysis]
403 van Veldhuisen E, Walma MS, van Rijssen LB, Busch OR, Bruijnen RCG, van Delden OM, Mohammad NH, de Hingh IH, Yo LS, van Laarhoven HW, van Leeuwen MS, Nio CY, van Santvoort HC, de Vries J, Wessels FJ, Wilmink JW, Molenaar IQ, Besselink MG, van Lienden KP; Dutch Pancreatic Cancer Group. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. HPB (Oxford) 2019;21:1385-92. [PMID: 31010633 DOI: 10.1016/j.hpb.2019.02.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
404 Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017;17:94. [PMID: 28841916 DOI: 10.1186/s12893-017-0291-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
405 Hao L, Zeng XP, Xin L, Wang D, Pan J, Bi YW, Ji JT, Du TT, Lin JH, Zhang D, Ye B, Zou WB, Chen H, Xie T, Li BR, Zheng ZH, Wang T, Guo HL, Liao Z, Li ZS, Hu LH. Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients. Dig Liver Dis. 2017;49:1249-1256. [PMID: 28756974 DOI: 10.1016/j.dld.2017.07.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
406 Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, Van Laethem JL, Eisendrath P. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Endosc Int Open. 2021;9:E253-E257. [PMID: 33553589 DOI: 10.1055/a-1324-2892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Powell-Brett S, Pande R, Roberts KJ. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:1669. [PMID: 33916294 DOI: 10.3390/cancers13071669] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
408 Bosch X, Moreno P, Guerra-García M, Guasch N, López-Soto A. What is the relevance of an ambulatory quick diagnosis unit or inpatient admission for the diagnosis of pancreatic cancer? A retrospective study of 1004 patients. Medicine (Baltimore) 2020;99:e19009. [PMID: 32176029 DOI: 10.1097/MD.0000000000019009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Feliu J, Jorge Fernández M, Macarulla T, Massuti B, Albero A, González González JF, Quintero-Aldana G, Delgado-Mingorance JI, Fernández Montes A, García Piernavieja C, Valladares-Ayerbes M, López Muñoz AM, Mondéjar Solís R, Vicente P, Casado Gonzalez E, González Cebrián I, López-Vivanco G. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemother Pharmacol 2021;87:543-53. [PMID: 33452559 DOI: 10.1007/s00280-020-04214-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
410 Aigner KR, Gailhofer S, Selak E, Aigner K. Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. J Cancer Res Clin Oncol 2019;145:2855-62. [PMID: 31506738 DOI: 10.1007/s00432-019-03019-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
411 Marcon F, Zuo J, Pearce H, Nicol S, Margielewska-Davies S, Farhat M, Mahon B, Middleton G, Brown R, Roberts KJ, Moss P. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology 2020;9:1845424. [PMID: 33299656 DOI: 10.1080/2162402X.2020.1845424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
412 Peng C, Zhou D, Meng L, Cao Y, Zhang H, Pan Z, Lin C. The value of combined vein resection in pancreaticoduodenectomy for pancreatic head carcinoma: a meta-analysis. BMC Surg 2019;19:84. [PMID: 31286916 DOI: 10.1186/s12893-019-0540-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
413 Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer 2021;151:14-24. [PMID: 33957442 DOI: 10.1016/j.ejca.2021.03.028] [Reference Citation Analysis]
414 Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Kawamoto Y, Suzuki R, Shirakawa H, Nagano H, Ueno M, Morizane C, Furuse J. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer. 2020;20:946. [PMID: 33004032 DOI: 10.1186/s12885-020-07462-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
415 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, de Gruijl TD, Scheffer HJ, Meijerink MR. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Curr Oncol Rep 2021;23:68. [PMID: 33864144 DOI: 10.1007/s11912-021-01057-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Su YY, Liu YS, Chao YJ, Chiang NJ, Yen CJ, Tsai HM. Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors. J Clin Med 2019;8:E1633. [PMID: 31590391 DOI: 10.3390/jcm8101633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
417 Bjerring OS, Hess S, Petersen H, Fristrup CW, Lundell L, Mortensen MB. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer. BJS Open 2021;5:zraa028. [PMID: 33688946 DOI: 10.1093/bjsopen/zraa028] [Reference Citation Analysis]
418 Armstrong A, Haque MR, Mirbagheri S, Barlass U, Gilbert DZ, Amin J, Singh A, Naqib A, Bishehsari F. Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma. Biomedicines 2021;9:705. [PMID: 34201419 DOI: 10.3390/biomedicines9070705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Martinez-Useros J, Georgiev-Hristov T, Fernández-Aceñero MJ, Borrero-Palacios A, Indacochea A, Guerrero S, Li W, Cebrián A, Gómez Del Pulgar T, Puime-Otin A, Del Puerto-Nevado L, Rodríguez-Remírez M, Pérez N, Celdrán A, Gebauer F, Garcia-Foncillas J. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. PLoS One 2017;12:e0182044. [PMID: 28763470 DOI: 10.1371/journal.pone.0182044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
420 Quilbe A, Moralès O, Baydoun M, Kumar A, Mustapha R, Murakami T, Leroux B, de Schutter C, Thecua E, Ziane L, Colombeau L, Frochot C, Mordon S, Delhem N. An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma. J Clin Med 2020;9:E192. [PMID: 31936786 DOI: 10.3390/jcm9010192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
421 Ucal Y, Durer ZA, Atak H, Kadioglu E, Sahin B, Coskun A, Baykal AT, Ozpinar A. Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases. Biochim Biophys Acta Proteins Proteom 2017;1865:795-816. [PMID: 28087424 DOI: 10.1016/j.bbapap.2017.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
422 Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021;25:179-91. [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179] [Reference Citation Analysis]
423 Anger F, Döring A, van Dam J, Lock JF, Klein I, Bittrich M, Germer CT, Wiegering A, Kunzmann V, van Eijck C, Löb S. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Ann Surg Oncol 2021;28:2325-36. [PMID: 32920720 DOI: 10.1245/s10434-020-09100-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
424 Mouhid L, Gómez de Cedrón M, Vargas T, García-Carrascosa E, Herranz N, García-Risco M, Reglero G, Fornari T, Ramírez de Molina A. Identification of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae plant extracts. BMC Complement Altern Med 2018;18:254. [PMID: 30223811 DOI: 10.1186/s12906-018-2322-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
425 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. BMC Cancer 2018;18:371. [PMID: 29614981 DOI: 10.1186/s12885-018-4276-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
426 Duan H, Baratto L, Laudicella R, Stracuzzi F, Baldari S, Iagaru A. Molecular imaging of pancreatic neoplasms. Clin Transl Imaging 2021;9:141-51. [DOI: 10.1007/s40336-020-00408-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Vogel JA, Rombouts SJ, de Rooij T, van Delden OM, Dijkgraaf MG, van Gulik TM, van Hooft JE, van Laarhoven HW, Martin RC, Schoorlemmer A, Wilmink JW, van Lienden KP, Busch OR, Besselink MG. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann Surg Oncol. 2017;24:2734-2743. [PMID: 28560601 DOI: 10.1245/s10434-017-5900-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 10.2] [Reference Citation Analysis]
428 Wenzel P, von Figura G. [Diagnostics and therapy of pancreatic carcinoma]. Dtsch Med Wochenschr 2021;146:246-52. [PMID: 33592660 DOI: 10.1055/a-1221-7306] [Reference Citation Analysis]
429 Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL, Brunner TB. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol 2017;193:433-43. [PMID: 28138949 DOI: 10.1007/s00066-017-1099-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
430 Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1-10. [PMID: 31163334 DOI: 10.1016/j.ctrv.2019.05.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
431 Lee YS, Lee JC, Kim JH, Kim J, Hwang JH. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Sci Rep 2021;11:20152. [PMID: 34635731 DOI: 10.1038/s41598-021-99647-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Chan MY, Chok KSH. Sarcopenia in pancreatic cancer – effects on surgical outcomes and chemotherapy. World J Gastrointest Oncol 2019; 11(7): 527-537 [PMID: 31367272 DOI: 10.4251/wjgo.v11.i7.527] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
433 Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 2020;4:100-8. [PMID: 32258974 DOI: 10.1002/ags3.12311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
434 Luo Y. The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database. Clin Transl Oncol 2021. [PMID: 34219204 DOI: 10.1007/s12094-021-02671-0] [Reference Citation Analysis]
435 Dayyani F, Morgenstern D, Holdenrieder S. In Response to “Serum Tumor Marker Use in Patients With Advanced Solid Tumors”. JOP 2016;12:273-4. [DOI: 10.1200/jop.2015.009241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
436 Xu F, Zhang Z, Zhao Y, Zhou Y, Pei H, Bai L. Bioinformatic mining and validation of the effects of ferroptosis regulators on the prognosis and progression of pancreatic adenocarcinoma. Gene 2021;795:145804. [PMID: 34175402 DOI: 10.1016/j.gene.2021.145804] [Reference Citation Analysis]
437 Beleù A, Calabrese A, Rizzo G, Capelli P, Bellini N, Caloggero S, Calbi R, Tinazzi Martini P, De Robertis R, Carbognin G, Marchegiani G, Scarpa A, Salvia R, Bassi C, D'Onofrio M. Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Cancers (Basel) 2019;11:E267. [PMID: 30823544 DOI: 10.3390/cancers11020267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
438 Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg 2021. [PMID: 34628591 DOI: 10.1007/s13304-021-01186-1] [Reference Citation Analysis]
439 Lindemann J, du Toit L, Kotze U, Bernon M, Krige J, Jonas E. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. HPB (Oxford) 2021;23:173-86. [PMID: 33268268 DOI: 10.1016/j.hpb.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, Yamao K, Imaoka H, Kawai M, Hirono S, Okada KI, Yamaue H. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.Int J Cancer. 2017;140:973-982. [PMID: 27861852 DOI: 10.1002/ijc.30510] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
441 Muñoz Martín AJ, Adeva J, Martínez-Galán J, Reina JJ, Hidalgo M. Pancreatic ductal adenocarcinoma: metastatic disease. Clin Transl Oncol 2017;19:1423-9. [PMID: 28623515 DOI: 10.1007/s12094-017-1690-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
442 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics (Basel) 2021;11:1195. [PMID: 34209310 DOI: 10.3390/diagnostics11071195] [Reference Citation Analysis]
443 Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treat Rev. 2016;50:142-147. [PMID: 27676174 DOI: 10.1016/j.ctrv.2016.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
444 He C, Wang J, Sun S, Zhang Y, Lin X, Lao X, Cui B, Li S. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. BMC Cancer. 2019;19:394. [PMID: 31029111 DOI: 10.1186/s12885-019-5607-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
445 O'reilly D, Fou L, Hasler E, Hawkins J, O'connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, Mcgeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology 2018;18:962-70. [DOI: 10.1016/j.pan.2018.09.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
446 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Le AT, Tzeng CW. Does finding early recurrence improve outcomes, and at what cost? J Surg Oncol 2016;114:329-35. [PMID: 27393742 DOI: 10.1002/jso.24370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
448 Tartaglione S, Mancini P, Viggiani V, Chirletti P, Angeloni A, Anastasi E. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. PLoS One 2021;16:e0251656. [PMID: 34015010 DOI: 10.1371/journal.pone.0251656] [Reference Citation Analysis]
449 Daamen LA, Dorland G, Brada LJH, Groot VP, van Oosten AF, Besselink MG, Bosscha K, Bonsing BA, Busch OR, Cirkel GA, van Dam RM, Festen S, Groot Koerkamp B, Haj Mohammad N, van der Harst E, de Hingh IHJT, Intven MPW, Kazemier G, Los M, de Meijer VE, Nieuwenhuijs VB, Roos D, Schreinemakers JMJ, Stommel MWJ, Verdonk RC, Verkooijen HM, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01624-5. [PMID: 34642090 DOI: 10.1016/j.hpb.2021.09.004] [Reference Citation Analysis]
450 Tsurusaki M, Numoto I, Oda T, Wakana M, Suzuki A, Yagyu Y, Matsuki M, Ishii K. Assessment of Liver Metastases Using CT and MRI Scans in Patients with Pancreatic Ductal Adenocarcinoma: Effects of Observer Experience on Diagnostic Accuracy. Cancers (Basel) 2020;12:E1455. [PMID: 32503262 DOI: 10.3390/cancers12061455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
451 Kiss B, Mikó E, Sebő É, Toth J, Ujlaki G, Szabó J, Uray K, Bai P, Árkosy P. Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma. Cancers (Basel) 2020;12:E1068. [PMID: 32344895 DOI: 10.3390/cancers12051068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
452 Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol 2021;44:519-25. [PMID: 34366400 DOI: 10.1097/COC.0000000000000856] [Reference Citation Analysis]
453 Conti CB, Cereatti F, Grassia R. Endoscopic ultrasound-guided sampling of solid pancreatic masses: the fine needle aspiration or fine needle biopsy dilemma. Is the best needle yet to come? World J Gastrointest Endosc 2019; 11(8): 454-471 [PMID: 31523377 DOI: 10.4253/wjge.v11.i8.454] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
454 Colloca G. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis. Asia Pac J Clin Oncol 2021. [PMID: 34161667 DOI: 10.1111/ajco.13598] [Reference Citation Analysis]
455 Dyhl-Polk A, Vaage-Nilsen M, Schou M, Vistisen KK, Lund CM, Kümler T, Appel JM, Nielsen DL. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol 2020;59:475-83. [PMID: 31931649 DOI: 10.1080/0284186X.2019.1711164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
456 Batista S, Gregório AC, Hanada Otake A, Couto N, Costa-Silva B. The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. J Oncol 2019;2019:6240505. [PMID: 31885581 DOI: 10.1155/2019/6240505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
457 Kieler M, Unseld M, Bianconi D, Prager GW. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo 2017;10:136-40. [PMID: 28989542 DOI: 10.1007/s12254-017-0352-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
458 Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d’Engremont C, Dupont-gossart A, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
459 Schneider M, Labgaa I, Vrochides D, Zerbi A, Nappo G, Perinel J, Adham M, van Roessel S, Besselink M, Mieog JSD, Groen JV, Demartines N, Schäfer M, Joliat G. External validation of three lymph node ratio-based nomograms predicting survival using an international cohort of patients with resected pancreatic head ductal adenocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.002] [Reference Citation Analysis]
460 Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019;9:1280-7. [PMID: 30867830 DOI: 10.7150/thno.29247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
461 Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo PE, Azria D, Pèlegrin A, Larbouret C, Chardès T. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer 2019;145:1838-51. [PMID: 30882895 DOI: 10.1002/ijc.32273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
462 Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T, Öhler L. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? BMC Cancer 2019;19:28. [PMID: 30621630 DOI: 10.1186/s12885-018-5240-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
463 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
464 Chen YT, Huang ZP, Zhou ZW, He MM. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. Med Oncol 2016;33:122. [PMID: 27730526 DOI: 10.1007/s12032-016-0839-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
465 Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496. [PMID: 31024520 DOI: 10.3389/fimmu.2019.00496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
466 de Biase D, Acquaviva G, Visani M, Sanza V, Argento CM, De Leo A, Maloberti T, Pession A, Tallini G. Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel. Diagnostics (Basel) 2020;10:E250. [PMID: 32340363 DOI: 10.3390/diagnostics10040250] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
467 Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol 2019;45:1770-7. [PMID: 31204168 DOI: 10.1016/j.ejso.2019.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
468 Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020;5. [PMID: 31958291 DOI: 10.1136/esmoopen-2019-000587] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
469 Dyrla P, Gil J, Kosik K, Schneditz D, Saracyn M, Niemczyk S, Lubas A. Doppler tissue perfusion measurement is a sensitive and specific tool for a differentiation between malignant and inflammatory pancreatic tumors. PLoS One 2019;14:e0215944. [PMID: 31034484 DOI: 10.1371/journal.pone.0215944] [Reference Citation Analysis]
470 Meneses-medina MI, Gervaso L, Cella CA, Pellicori S, Gandini S, Sousa MJ, Fazio N. Chemotherapy in pancreatic ductal adenocarcinoma: when cytoreduction is the aim. A systematic review and meta-analysis. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102338] [Reference Citation Analysis]
471 Badovinac D, Goričar K, Zavrtanik H, Petrič M, Lavrin T, Mavec N, Dolžan V, Tomažič A, Lenassi M. Plasma Extracellular Vesicle Characteristics Correlate with Tumor Differentiation and Predict Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Curative Intent. J Pers Med 2021;11:77. [PMID: 33525618 DOI: 10.3390/jpm11020077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
472 Marques S, Bispo M, Rio-Tinto R, Fidalgo P, Devière J. The Impact of Recent Advances in Endoscopic Ultrasound-Guided Tissue Acquisition on the Management of Pancreatic Cancer. GE Port J Gastroenterol 2021;28:185-92. [PMID: 34056041 DOI: 10.1159/000510730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Seitz JF, Lepage C, François E; PRODIGE 35 Investigators/Collaborators. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. J Clin Oncol 2021;39:3242-50. [PMID: 34288696 DOI: 10.1200/JCO.20.03329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Schwarz L, Tortajada P, Pittau G, Di Fiore F, Sefrioui D, Bridoux V, Laurenzi A, Tuech J, Sa Cunha A. “Laparoscopic Para-Aortic Lymph Node Sampling” First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. Journal of Laparoendoscopic & Advanced Surgical Techniques 2019;29:900-4. [DOI: 10.1089/lap.2018.0775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
475 Vitello DJ, Bentrem DJ. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. J Surg Oncol 2021;123:1449-59. [PMID: 33831249 DOI: 10.1002/jso.26369] [Reference Citation Analysis]
476 Schlick K, Hohla F, Hamacher F, Hackl H, Hufnagl C, Markus S, Magnes T, Gampenrieder SP, Melchardt T, Stättner S, Hauser-Kronberger C, Greil R, Rinnerthaler G. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. Future Sci OA 2020;7:FSO644. [PMID: 33437513 DOI: 10.2144/fsoa-2020-0128] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
477 Deyev SM, Vorobyeva A, Schulga A, Abouzayed A, Günther T, Garousi J, Konovalova E, Ding H, Gräslund T, Orlova A, Tolmachev V. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. Int J Biol Macromol 2020;145:216-25. [PMID: 31863835 DOI: 10.1016/j.ijbiomac.2019.12.147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
478 Boevers E, McDowell BD, Mott SL, Button AM, Lynch CF. Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma. J Cancer Epidemiol 2017;2017:4354592. [PMID: 28487737 DOI: 10.1155/2017/4354592] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
479 Tabchouri N, Bouquot M, Hermand H, Benoit O, Loiseau J, Dokmak S, Aussilhou B, Gaujoux S, Turrini O, Delpero JR, Sauvanet A. A Novel Pancreatic Fistula Risk Score Including Preoperative Radiation Therapy in Pancreatic Cancer Patients. J Gastrointest Surg 2021;25:991-1000. [DOI: 10.1007/s11605-020-04600-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
480 Stotz M, Barth DA, Riedl JM, Asamer E, Klocker EV, Kornprat P, Hutterer GC, Prinz F, Lackner K, Stöger H, Gerger A, Pichler M. The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Cancers (Basel) 2020;12:E1798. [PMID: 32635610 DOI: 10.3390/cancers12071798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Malakhov N, Lee A, Albert A, Lederman A, Byun J, Safdieh J, Schreiber D. Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma. J Gastrointest Cancer 2020;51:506-14. [PMID: 31236851 DOI: 10.1007/s12029-019-00265-2] [Reference Citation Analysis]
482 Xing J, Yang B, Hou X, Jia N, Gong X, Li X, Zhou N, Cheng Y, Bai C. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection. Front Oncol 2021;11:660215. [PMID: 34631515 DOI: 10.3389/fonc.2021.660215] [Reference Citation Analysis]
483 Bonnet E, Mastier C, Lardy-Cléaud A, Rochefort P, Sarabi M, Guibert P, Cattey-Javouhey A, Desseigne F, de La Fouchardière C. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study. Curr Oncol 2019;26:e466-72. [PMID: 31548814 DOI: 10.3747/co.26.4903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
484 Kato T, Ban D, Tateishi U, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. J Hepatobiliary Pancreat Sci 2020;27:114-23. [PMID: 31702106 DOI: 10.1002/jhbp.700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
485 Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19:97-104. [PMID: 30529068 DOI: 10.1016/j.pan.2018.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
486 Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019;9:e033452. [PMID: 31818843 DOI: 10.1136/bmjopen-2019-033452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
487 Quero G, Salvatore L, Fiorillo C, Bagalà C, Menghi R, Maria B, Cina C, Laterza V, Di Stefano B, Maratta MG, Ribelli M, Galiandro F, Mattiucci GC, Brizi MG, Genco E, D'Aversa F, Zileri L, Attili F, Larghi A, Perri V, Inzani F, Gasbarrini A, Valentini V, Costamagna G, Manfredi R, Tortora G, Alfieri S. The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. ESMO Open 2021;6:100010. [PMID: 33399076 DOI: 10.1016/j.esmoop.2020.100010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
488 Beetz O, Sarisin A, Kaltenborn A, Klempnauer J, Winkler M, Grannas G. Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis. World J Surg Oncol 2020;18:218. [PMID: 32819373 DOI: 10.1186/s12957-020-01973-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
489 Boces-Pascual C, Mata-Ventosa A, Martín-Satué M, Boix L, Gironella M, Pastor-Anglada M, Pérez-Torras S. OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1. Cell Mol Life Sci 2021. [PMID: 34647142 DOI: 10.1007/s00018-021-03959-8] [Reference Citation Analysis]
490 Hu Q, Wang X, Chen Y, Li X, Cao P, Cao D. Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98:e15761. [PMID: 31124963 DOI: 10.1097/MD.0000000000015761] [Reference Citation Analysis]
491 Su YY, Chiang NJ, Tsai HJ, Yen CJ, Shan YS, Chen LT. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Sci Rep 2020;10:7420. [PMID: 32366911 DOI: 10.1038/s41598-020-64421-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
492 van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HW, van Lienden KP, Wilmink JW, Marsman HA, Besselink MG. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB 2018;20:605-11. [DOI: 10.1016/j.hpb.2018.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
493 Burgdorf SK, Storkholm JH, Chen IM, Hansen CP. Postoperative and long-term survival in relation to life-expectancy after pancreatic surgery in elderly patients (cohort study). Ann Med Surg (Lond) 2021;69:102724. [PMID: 34457257 DOI: 10.1016/j.amsu.2021.102724] [Reference Citation Analysis]
494 Kirkegård J, Al-Saiddi M, Bratlie SO, Coolsen M, de Haas RJ, den Dulk M, Fristrup C, Greve OJ, Harrison E, Koutouzi G, Miclea RL, Mortensen MB, Nijkamp MW, Persson J, Robertson FP, Slangen JJG, Søreide JA, Wigmore SJ, Mortensen FV. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. J Surg Oncol 2021. [PMID: 34490905 DOI: 10.1002/jso.26670] [Reference Citation Analysis]
495 Fujiwara K, Saung MT, Jing H, Herbst B, Zarecki M, Muth S, Wu A, Bigelow E, Chen L, Li K, Jurcak N, Blair AB, Ding D, Wichroski M, Blum J, Cheadle N, Koenitzer J, Zheng L. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. J Immunother Cancer 2020;8:e000351. [PMID: 32675194 DOI: 10.1136/jitc-2019-000351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
496 Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Front Surg 2022;9:866173. [DOI: 10.3389/fsurg.2022.866173] [Reference Citation Analysis]
497 Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging 2016;97:1225-32. [PMID: 27692675 DOI: 10.1016/j.diii.2016.07.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
498 Chun JW, Lee SH, Kim JS, Park N, Huh G, Cho IR, Paik WH, Ryu JK, Kim YT. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 2021;21:537. [PMID: 33975561 DOI: 10.1186/s12885-021-08277-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
499 Aoyama R, Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Yazawa T, Sasaki B, Tani M, Sato A, Katsura H, Kamada Y, Tani R, Sasaki Y, Zaima M. A Thought-Provoking Case of Successfully Treated Carcinoma of the Head of the Pancreas with Metachronous Lung Metastasis: Impact of Distal Spleno-Renal Shunt for Regional Invasion on Long-Term Period after Pancreaticoduodenectomy. Case Rep Surg 2021;2021:6689419. [PMID: 34136302 DOI: 10.1155/2021/6689419] [Reference Citation Analysis]
500 Rombouts SJE, Derksen TC, Nio CY, van Hillegersberg R, van Santvoort HC, Walma MS, Molenaar IQ, van Leeuwen MS. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. Abdom Radiol (NY) 2018;43:2702-11. [PMID: 29492602 DOI: 10.1007/s00261-018-1519-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
501 Schmidt T, Belyaev O, Uhl W, Bruns CJ. [Surgical treatment of pancreatic cancer-What is new?]. Chirurg 2022. [PMID: 35357553 DOI: 10.1007/s00104-022-01618-7] [Reference Citation Analysis]
502 Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I. [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg 2020;91:319-28. [PMID: 31828387 DOI: 10.1007/s00104-019-01072-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
503 De Mello RA, Faleiro I, Apolónio JD, Tabori U, Price AJ, Roberto VP, Castelo-Branco P. Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends. Future Oncol 2019;15:683-5. [PMID: 30693809 DOI: 10.2217/fon-2018-0153] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
504 De Cobelli F, Marra P, Diana P, Brembilla G, Venturini M. Therapeutic EUS: Biliary drainage - The interventional radiologist's perspective. Endosc Ultrasound. 2017;6:S127-S131. [PMID: 29387709 DOI: 10.4103/eus.eus_77_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
505 Li YF, Xiang YC, Zhang QQ, Wang WL. Impact of examined lymph node count on prognosis in patients with lymph node-negative pancreatic body/tail ductal adenocarcinoma. J Gastrointest Oncol 2020;11:644-53. [PMID: 32953148 DOI: 10.21037/jgo-20-158] [Reference Citation Analysis]
506 Toshiyama R, Noda T, Eguchi H, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Morii E, Umeshita K, Mori M, Doki Y. Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case reports. Surg Case Rep 2017;3:39. [PMID: 28238191 DOI: 10.1186/s40792-017-0314-2] [Reference Citation Analysis]
507 Pelzer U, Wislocka L, Jühling A, Striefler J, Klein F, Roemmler-Zehrer J, Sinn M, Denecke T, Bahra M, Riess H. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis. Eur J Cancer 2018;100:85-93. [PMID: 30014884 DOI: 10.1016/j.ejca.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
508 Kim GP, Surinach A, Corvino FA, Cockrum P, Belanger B, Abushahin L. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Future Oncol 2021;17:675-88. [PMID: 33070660 DOI: 10.2217/fon-2020-0902] [Reference Citation Analysis]
509 Tian J, Zhu Y, Rao M, Cai Y, Lu Z, Zou D, Peng X, Ying P, Zhang M, Niu S, Li Y, Zhong R, Chang J, Miao X. N6-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut 2020;69:2180-92. [PMID: 32312789 DOI: 10.1136/gutjnl-2019-320179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
510 Macarulla T, Fernández T, Gallardo ME, Hernando O, López AM, Hidalgo M. Adjuvant treatment for pancreatic ductal carcinoma. Clin Transl Oncol 2017;19:1199-204. [PMID: 28639051 DOI: 10.1007/s12094-017-1683-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
511 Sánchez Morales G, Moguel Valladares R, Flores Maza J, Clemente Gutiérrez U, Sánchez-garcía Ramos E, Domínguez Rosado I, Chan Núñez L. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Revista de Gastroenterología de México (English Edition) 2021;86:118-24. [DOI: 10.1016/j.rgmxen.2020.04.005] [Reference Citation Analysis]
512 Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, Cunha AS, Vienot A, Lecomte T, Hautefeuille V, de La Fouchardière C, Sarabi M, Ksontini F, Forestier J, Coriat R, Fabiano E, Leroy F, Williet N, Bachet JB, Tougeron D, Taieb J. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer 2021;124:1941-8. [PMID: 33772154 DOI: 10.1038/s41416-021-01341-w] [Reference Citation Analysis]
513 Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer 2018;18:1185. [PMID: 30497432 DOI: 10.1186/s12885-018-5101-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
514 Pittella-Silva F, Kimura Y, Low SK, Nakamura Y, Motoya M. Amplification of mutant KRASG12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. Mol Clin Oncol 2021;15:172. [PMID: 34276991 DOI: 10.3892/mco.2021.2334] [Reference Citation Analysis]
515 Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB 2017;19:83-92. [DOI: 10.1016/j.hpb.2016.11.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
516 Diwakarla C, Hannan K, Hein N, Yip D. Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. World J Gastroenterol 2017; 23(13): 2276-2285 [PMID: 28428707 DOI: 10.3748/wjg.v23.i13.2276] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
517 Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Ann Surg Oncol 2020;27:2017-24. [PMID: 31900809 DOI: 10.1245/s10434-019-08161-6] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
518 Zhang X, Zhang J, Fan H, Liu Y, He Q. Risk factors related to metastasis of para-aortic lymph nodes in pancreatic ductal adenocarcinoma: A retrospective observational study. Medicine (Baltimore) 2018;97:e12370. [PMID: 30290595 DOI: 10.1097/MD.0000000000012370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Antonini F, Fuccio L, Giorgini S, Fabbri C, Frazzoni L, Scarpelli M, Macarri G. Biliary plastic stent does not influence the accuracy of endoscopic ultrasound-guided sampling of pancreatic head masses performed with core biopsy needles. Dig Liver Dis 2017;49:898-902. [PMID: 28465092 DOI: 10.1016/j.dld.2017.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
520 Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers (Basel). 2018;10. [PMID: 29320420 DOI: 10.3390/cancers10010016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
521 Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, van Santvoort HC, Molenaar IQ. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. J Surg Res 2018;221:152-60. [PMID: 29229122 DOI: 10.1016/j.jss.2017.08.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
522 Panje CM, Glatzer M, Sirén C, Plasswilm L, Putora PM. Treatment Options in Oncology. JCO Clin Cancer Inform 2018;2:1-10. [PMID: 30652608 DOI: 10.1200/CCI.18.00017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
523 Diab HMH, Smith HG, Jensen KK, Jørgensen LN. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. Eur J Cancer 2021;154:73-81. [PMID: 34243080 DOI: 10.1016/j.ejca.2021.05.033] [Reference Citation Analysis]
524 Connell CM, Brais R, Whitaker H, Upponi S, Beh I, Risdall J, Corrie P, Janowitz T, Jodrell DI. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report. BMC Cancer 2020;20:38. [PMID: 31941506 DOI: 10.1186/s12885-020-6516-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
525 Harder FN, Jungmann F, Kaissis GA, Lohöfer FK, Ziegelmayer S, Havel D, Quante M, Reichert M, Schmid RM, Demir IE, Friess H, Wildgruber M, Siveke J, Muckenhuber A, Steiger K, Weichert W, Rauscher I, Eiber M, Makowski MR, Braren RF. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res 2021;11:70. [PMID: 34322781 DOI: 10.1186/s13550-021-00808-4] [Reference Citation Analysis]
526 Nießen A, Schimmack S, Weber TF, Mayer P, Bergmann F, Hinz U, Büchler MW, Strobel O. Presentation and outcome of mixed neuroendocrine non-neuroendocrine neoplasms of the pancreas. Pancreatology 2021;21:224-35. [PMID: 33309225 DOI: 10.1016/j.pan.2020.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
527 Samawi HH, Yin Y, Lim HJ, Cheung WY. Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. J Gastrointest Canc 2018;49:429-36. [DOI: 10.1007/s12029-017-9988-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
528 Pop VV, Seicean A, Lupan I, Samasca G, Burz CC. IL-6 roles - Molecular pathway and clinical implication in pancreatic cancer - A systemic review. Immunol Lett. 2017;181:45-50. [PMID: 27876525 DOI: 10.1016/j.imlet.2016.11.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
529 Litjens G, Rivière DM, van Geenen EJM, Radema SA, Brosens LAA, Prokop M, van Laarhoven CJHM, Hermans JJ. Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic cancer - DIA-PANC study: study protocol for an international, multicenter, diagnostic trial. BMC Cancer 2020;20:744. [PMID: 32778061 DOI: 10.1186/s12885-020-07226-0] [Reference Citation Analysis]
530 Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Žakelj M, Zadnik V, Becker N, Hackert T, Mägi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019;68:130-9. [PMID: 29158237 DOI: 10.1136/gutjnl-2017-314828] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
531 Chen L, Zhou D, Liu Z, Huang X, Liu Q, Kang Y, Chen Z, Guo Y, Zhu H, Sun C. Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncol Rep. 2018;39:1081-1089. [PMID: 29328487 DOI: 10.3892/or.2018.6198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
532 Gamradt P, De La Fouchardière C, Hennino A. Stromal Protein-Mediated Immune Regulation in Digestive Cancers. Cancers (Basel) 2021;13:E146. [PMID: 33466303 DOI: 10.3390/cancers13010146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
533 Moutinho-ribeiro P, Iglesias-garcia J, Gaspar R, Macedo G. Early pancreatic cancer — The role of endoscopic ultrasound with or without tissue acquisition in diagnosis and staging. Digestive and Liver Disease 2019;51:4-9. [DOI: 10.1016/j.dld.2018.09.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
534 Ohwada S, Moro A, Amit N, Sasaki K, Sakurai S, Takada-Owada A, Izumi M, Nakano Y, Kashima Y, Matsuyama H. A case of 18 years disease-free survival after combined pancreatoduodenectomy and hemicolectomy for carcinosarcoma of the transverse colon. Surg Case Rep 2021;7:76. [PMID: 33765265 DOI: 10.1186/s40792-021-01159-x] [Reference Citation Analysis]
535 Rah B, Banday MA, Bhat GR, Shah OJ, Jeelani H, Kawoosa F, Yousuf T, Afroze D. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer. World J Gastroenterol 2021; 27(36): 6093-6109 [PMID: 34629822 DOI: 10.3748/wjg.v27.i36.6093] [Reference Citation Analysis]
536 Gesualdo M, Rizzi F, Bonetto S, Rizza S, Cravero F, Saracco GM, De Angelis CG. Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives. J Clin Med 2020;9:E3535. [PMID: 33139601 DOI: 10.3390/jcm9113535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
538 Hutt E, Da Silva A, Bogart E, Le Lay-Diomande S, Pannier D, Delaine-Clisant S, Le Deley MC, Adenis A. Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial. BMJ Open 2018;8:e015904. [PMID: 29362244 DOI: 10.1136/bmjopen-2017-015904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
539 Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol 2019; 25(12): 1524-1530 [PMID: 30948915 DOI: 10.3748/wjg.v25.i12.1524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
540 Jefremow A, Neurath MF. Nanoparticles in Gastrooncology. Visc Med 2020;36:88-94. [PMID: 32355665 DOI: 10.1159/000506908] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
541 Su Q, Zhu EC, Qu YL, Wang DY, Qu WW, Zhang CG, Wu T, Gao ZH. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. J Cancer 2018;9:3991-9. [PMID: 30410604 DOI: 10.7150/jca.27697] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
542 Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Muñoz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). J Clin Oncol 2021;39:1108-18. [PMID: 33555926 DOI: 10.1200/JCO.20.02232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
543 Nguyen LT, Do DH, Van Nguyen H, Nguyen KT, Nguyen CD. Lymph Node Characteristics and Short-Term Outcomes for Resectable Pancreatic Ductal Adenocarcinoma in Vietnam: A Retrospective Single-Center Study. Indian J Surg. [DOI: 10.1007/s12262-022-03344-0] [Reference Citation Analysis]
544 Carreira NR, Gonçalves C, Wahnon A, Dâmaso S, Martins J. Late Diagnosis of Maturity-Onset Diabetes of the Young (MODY) 12 With Catastrophic Consequences. Cureus 2021;13:e13145. [PMID: 33728157 DOI: 10.7759/cureus.13145] [Reference Citation Analysis]
545 Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers (Basel) 2021;13:1612. [PMID: 33807330 DOI: 10.3390/cancers13071612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H, Nakai Y, Imai S, Okamura S. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Br J Cancer 2017;116:1544-50. [PMID: 28472821 DOI: 10.1038/bjc.2017.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
547 Lutsyk M, Ben-Yosef R. The Role of Radiotherapy in Resected R0/R+ Pancreatic Cancer: A Real-Life Single-Institution Experience. Am J Clin Oncol 2020;43:187-92. [PMID: 31842116 DOI: 10.1097/COC.0000000000000653] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
548 Ferencz A, Lőrinczy D. DSC measurements of blood plasma on patients with chronic pancreatitis and operable and inoperable pancreatic adenocarcinoma. J Therm Anal Calorim 2017;127:1187-92. [DOI: 10.1007/s10973-016-5371-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
549 Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol 2020;32:356-63. [PMID: 32541325 DOI: 10.1097/CCO.0000000000000639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
550 Grenacher L, Juchems M. Resektabilitätskriterien beim Pankreaskarzinom und postoperative Bildgebung. Radiologe 2017;57:1075-90. [DOI: 10.1007/s00117-017-0326-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
551 Williet N, Di Bernardo T, Vernet C, Roche LS, Muron T, Roblin X, Magne N, Phelip JM. Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. Oncotarget 2018;9:31999-2009. [PMID: 30174792 DOI: 10.18632/oncotarget.25877] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
552 Lundy J, Harris M, Zalcberg J, Zimet A, Goldstein D, Gebski V, Borsaru A, Desmond C, Swan M, Jenkins BJ, Croagh D. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Front Oncol 2021;11:770022. [PMID: 34956889 DOI: 10.3389/fonc.2021.770022] [Reference Citation Analysis]
553 Frei L, Stieger R, Bayerl C, Breitenstein S, Staerkle RF. Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report. J Med Case Rep 2017;11:194. [PMID: 28716115 DOI: 10.1186/s13256-017-1359-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
554 Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 2017;79:41-9. [PMID: 28460245 DOI: 10.1016/j.ejca.2017.03.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
555 Lin KI, Yang JL, Lin YC, Chou CY, Chen JH, Hung CC. Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer. Cancers (Basel) 2019;11:E1746. [PMID: 31703359 DOI: 10.3390/cancers11111746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
556 Blomstrand H, Adolfsson K, Sandström P, Björnsson B. Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy. Case Rep Gastrointest Med 2020;2020:4138215. [PMID: 32099693 DOI: 10.1155/2020/4138215] [Reference Citation Analysis]
557 Franck C, Canbay A, Malfertheiner P, Venerito M. Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. J Oncol 2019;2019:5832309. [PMID: 31885579 DOI: 10.1155/2019/5832309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
558 Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Eur J Cancer 2021;151:3-13. [PMID: 33951545 DOI: 10.1016/j.ejca.2021.03.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
559 Schlanger D, Popa C, Pașca S, Seicean A, Al Hajjar N. The role of systemic immuno-inflammatory factors in resectable pancreatic adenocarcinoma: a cohort retrospective study. World J Surg Oncol 2022;20:144. [PMID: 35513845 DOI: 10.1186/s12957-022-02606-1] [Reference Citation Analysis]
560 Ahola R, Hölsä H, Kiskola S, Ojala P, Pirttilä A, Sand J, Laukkarinen J. Access to radical resections of pancreatic cancer is region-dependent despite the public healthcare system in Finland. J Epidemiol Community Health 2018;72:803-8. [PMID: 29720389 DOI: 10.1136/jech-2017-210187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
561 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
562 Shingyoji A, Mikata R, Ogasawara S, Kusakabe Y, Yasui S, Sugiyama H, Ohno I, Kato J, Takano S, Yoshitomi H, Ohtsuka M, Kato N. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Jpn J Clin Oncol. 2020;50:1403-1411. [PMID: 32761096 DOI: 10.1093/jjco/hyaa136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87:987-992. [PMID: 28803454 DOI: 10.1111/ans.14131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]